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3
ABSTRACT 
Children´s interstitial lung diseases (chILD) cover many rare entities, frequently not 
diagnosed or studied in detail. There is a great need for specialized advice and for 
internationally agreed sub-classification of entities collected in a register. 
Our objective was to implement an international management platform with 
independent multidisciplinary review of cases at presentation for long term follow up and to 
test if this would allow for more accurate diagnosis. Also quality and reproducibility of a 
diagnostic sub-classification system were assessed using a collection of 25 complex chILD 
cases. 
A web-based chILD management platform with a registry and biobank was 
successfully designed and implemented. Over a three-year period 575 patients were included 
for observation spanning a wide spectrum of chILD. In 346 patients multidisciplinary reviews 
were completed by teams at 5 international sites (Munich 51%, London 12%, Hannover 31%, 
Ankara 1% and Paris 5%). In 13% the diagnosis reached by the referring team was not 
confirmed by peer review. Among these, the diagnosis initially given was wrong (27%), 
imprecise (50%) or significant information was added (23%).  
The ability of nine expert clinicians to sub-categorize the final diagnosis into the 
chILD-EU register classification had an overall exact inter-rater agreement of 59% on first 
assessment and after training, 64%. Only 10% of the ‘wrong’ answers resulted in allocation to 
an incorrect category. Sub-categorization proved useful but training is needed for optimal 
implementation. 
 We have shown that chILD-EU has generated a platform to help the clinical 
assessment of chILD. 
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4
 
 
Short summary 
What is the key question? 
Can an international management platform for children´s interstitial lung disease (chILD) 
with independent multidisciplinary review be implemented and is the diagnostic sub-
classification reproducible? 
 
What is the bottom line? 
Well-functioning, web-based multi-disciplinary teams were successfully set up, and 
significantly changed 13% of the diagnoses submitted by pediatric pneumologists. Sub-
classification by review-teams proved useful and although training in implementation is 
needed. 
 
Why read on? 
So you can learn how the system works and use it in the future. 
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5
INTRODUCTION 
Children´s interstitial lung diseases (chILD) is an umbrella term covering many rare 
conditions, frequently not diagnosed because the presentation is non-specific; and many 
entities which are ill- defined or poorly studied. Chest imaging shows diffuse abnormalities 
and age-appropriate lung function tests are abnormal. The incidence of these rare diseases in 
Europe is 0.5 to 1 cases in 100.000. In the United Kingdom and Ireland prevalence was 
estimated as 3.6 per million children [1], and in Germany at 1.32 new cases per 1 million 
children/year [2]. Prevalence and incidence is likely greatly under-estimated due to 
misdiagnosis, lack of an ICD code allowing hospital based estimates of cases, and the absence 
of a common register. Extrapolation to Europe (about 500 million people, 80 million children 
< 14 years) suggests there are about 2000 known cases and an incident case rate of more than 
100 per year. The overall mortality in childhood is around 15% [2]. There are no evidence 
based treatments for any of the diseases [3]. 
 The experiences of physicians, as well as the relatives and the patients, who often have 
been through a real diagnostic odyssey, show that these patients often do not receive optimal 
care [4]. Progress is also very slow because of lack of technical resources for obtaining 
second opinions in complex individual cases and the absence of the sort of large, well-
characterized cohorts which are essential for the conduct of randomized clinical trials. In 
pediatric oncology similar problems were solved decades ago as registries for diagnosis, 
systematic treatment plans and sufficient financial support were established [5]. In pediatric 
respiratory medicine cystic fibrosis has led the way from simple registries to the establishment 
of clinical trial networks [6]. Networks have also been established for primary ciliary 
dyskinesia [7].  
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6
 In chILD there is a pressing need for both specialized diagnostic advice from 
international experts because of the rareness of individual diagnoses, and services to provide 
local care and therapy. Our objective was to implement an international management platform 
with independent multidisciplinary review of cases at presentation for long term follow up, to 
test if this would allow for more accurate diagnosis and thus provide structures for 
randomized controlled trials of treatment and translational studies. We here describe how we 
made such a platform and the chILD cases accumulated over a three-year period. The 
outcomes from an expert review process are reported, together with assessment of the intra-
observer consistency of expert reviewers, to help identify training requirements for clinical 
experts. We intend that this report will serve as a model for others setting up registries and 
biobanks across Europe in other diseases and disciplines. 
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7
METHODS 
Rationale and need for the chILD register 
 The international registry for chILD was established to fill the previously unmet need 
of an i ternational platform to systematically collect data from pediatric patients and allows 
all groups of professional and private stakeholders to participate in the care of chILD patients. 
The registry governance fulfils the widely varying legal, data protection and ethical 
requirements across Europe, without compromising access to the data. 
Eligibility criteria, consent and ethical approval 
 Patients are identified by their local physicians, who can register as participants in a 
referring center. Any referring center needs to ensure compliance with all necessary 
contractual legal and ethical requirements. The central register support team assists 
throughout this process. Each patient and/or care giver gave respectively age appropriate 
assent and written informed consent before any data were entered. The register and biobank 
study was approved by the responsible external lead ethics board, the Ethical Review 
Committee of the Ludwig-Maximilians University Munich, Germany (EK 111-13). The data 
safety protection processes of the register and biobank was approved by the Telematic 
Platform (TMF), an organization for networked medical research.  
 chILD was defined as entities originating from abnormalities of components of the 
lung parenchyma, which include the alveolar epithelium, vascular endothelium, interposed 
connective tissues and more centrally, the peribronchiolar and peribronchial tissues; airways 
may be involved as a secondary process [8]. chILD was suspected if there were (1) respiratory 
symptoms/signs such as cough, tachy- or dyspnea at rest or with exercise, crackles, 
retractions, clubbing, failure to thrive, respiratory failure, (2) systemic arterial hypoxemia, (3) 
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8
diffuse radiological abnormalities, and if both feasible and available (4) abnormalities in 
pulmonary function testing, usually for a minimum duration of 4 weeks, but shorter in cases 
of acute severe chILD (usually neonatal onset), in accord with standard practice  [9, 10]. We 
included all suspected chILD [11]. A case not confirmed as chILD after peer review could be 
followed as a disease control. All patients included were prospectively and longitudinally 
followed. Baseline was the time of inclusion into the register; both prevalent cases which 
were already under review at the inception of the platform, as well as incident, newly 
diagnosed cases, were followed. During follow-up, suitable chILD patients in the register 
study were eligible to enter randomized controlled trials set up in the Secutrial® database, if 
consent was given. 
Minimal data set and workflows of operation 
 Cases were entered into the register using minimal dataset (generation and data base 
dictionary see online supplement and Tab. S1), peer-reviewed, categorized [12] and followed 
over time. Automatic reminders were sent if follow up was due. Communication on cases was 
strictly within the database using a discussion tool automatically embedding the local 
physician, the peer reviewers and additional experts if wished, in order to pool information 
without compromising security.  
Data safety concept, data base and biobank 
 In accord with best practice data protection (http://www.tmf-
ev.de/EnglishSite/Home.aspx), there is an institutionally and organizationally separated 
storage of identifying (IDAT) and medical data (MDAT)(Supplement Fig. S1). The 
processing of the pseudonymized medical data is using SecuTrial®, which is US Food and 
Drug Administration (FDA)-compliant and is concordant with good clinical practice rules 
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9
(GCP). An additional SecuTrial®-database for managing biomaterials is the central biobank 
at Munich University Hospital (Supplement Fig. S2).  
Quality control 
 The register manager and register physicians carefully audit data completeness and 
score the quality of imaging and histological studies. Early in the project, the standards 
working group generated consensus-agreed diagnostic and management clinical guidelines 
[13]. Due to shortage of resources, no source data verification is currently in place. In addition 
to immediate individual feedback to the centers via the national coordinator, annual reports 
are generated for each center and the register.  
Peer review 
 A central novel element of the register was the involvement of a multidisciplinary team 
review board. Although this is routine in adult ILD [14], until now this has not been routine in 
Europe in chILD. The goal of peer review was to give advice on diagnosis and differential 
diagnosis, to insure adherence to diagnostic standards set previously [13], to have a case 
review independent of the submitting center, to use a harmonized categorization system [12] 
and to come up with a final working diagnosis. Peer review teams were composed of a 
respiratory paediatrician, a paediatric radiologist and pathologist; if necessary a geneticist was 
also consulted. The teams were constituted first on a national basis to establish the workflow 
within the management platform and then rolled out as an international resource. For online 
training Skype conferences with shared screen features were organized. Peer review was 
started as soon as all relevant clinical data, imaging (see online supplement) and histology 
glass slides were available for the reviewers.  
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10
 To assess the skills of categorization of the final working diagnosis by clinicians, 
we randomly selected 25 chILD cases (from the first 312 cases peer-reviewed) with a 
pulmonary and non-pulmonary diagnosis to be allocated to one of five given subcategories 
(Tab. S2). The correct selection was determined by a group of three pediatric pneumologists 
who were very familiar with the categorization system and strictly adhered to the previously 
set up categorization rules [12]. The test took about 30 to 45 minutes. Nine pediatric 
pneumologists with long standing experience and interests in chILD were asked to 
subcategorize, and this test was repeated after 3 months. In between, a video and interactive 
training “How to categorize chILD” was used for teaching. 
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11
RESULTS  
Register design – how the chILD-EU management platform works 
 After registration of the local physician, an educational and interactive training session 
is undertaken. When familiar with the system, the physician or coordinator enters the web-
based site to set up a new patient and enter the minimal data set necessary for peer review. 
This includes a structured referral letter and imaging. Individual support for data entry by the 
central registry is offered. Great care is taken to pseudonymise uploaded letters and reports, 
and radiological images are automatically pseudonymised during upload (Fig. S1). 
 Baseline data includes the entire past clinical course of the patient until entry into the 
data base (Fig 1, left column). chILD-specific patient reported outcomes were developed and 
validated, and together with developmentally adapted versions for different age groups now 
available on the chILD platform in different languages (details see online supplement), as is 
information on health-economic status. Data obtained on a single occasion, such as biopsy, 
lavage and genetics, and prospective observations of specific treatments are entered separately 
(Fig 1, right column). Information is exchanged and saved between local physician, data 
manager and peer reviewer via emails dispatched from the system and a discussion panel. 
Following review, diagnosis and categorization (see below), the patient is observed 
prospectively over time with entry of a limited dataset (Fig 1, middle column).  
 Material sent for central biobanking is indicated in the patient data set with a 
collection number, so that local physician can track material associated with each subject. Site 
staff at central biobank record what has been sent with a collection identifier, so they can 
track materials. Biomaterials are entered into the separately run biobank. The material 
remains the property of the patient and/or family all the time. 
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12
Enrolment and demography 
 From January 2014 to November 2016 575 patients (53% male) from 82 centres in 16 
countries were enrolled in the database (Table 1). The median age of the children at inclusion 
was 5.5 years (range 0 to 25; mean 7.0, SD 6.3) with an almost even distribution over time.  
Peer review of cases to establish final working diagnosis, disease category and subcategory 
 When a peer review has been requested, the national coordinating team receives a 
message with an embedded link to the case, checks for completeness of data and materials, 
and decides if the review process can be started or not (Fig. 2A). During the review meeting, 
the clinician presents the case using the referral letter; the images are demonstrated by the 
radiologists and the pathological review when relevant material is available is also presented. 
When needed genetic advice is also taken. After discussion the lead clinician summarizes the 
diagnosis, categorizes the case and concludes the peer review. An automatic message informs 
the site physician about the result and further recommendations.  
Results from peer reviewing by multidisciplinary review teams 
 Of the 575 patients included into the register for observation, 190 patients had 
insufficient data precluding the start of the peer review. In 385 patients peer review requests 
were accepted, 39 could not be finalized due to information for which the reviewers asked but 
was not forthcoming (Fig. 2B), and a total of 346 peer reviews completed. These were done 
by teams in Munich (n=176; 51%), London (n=43, 12%), Hannover (n=107, 31%), Ankara 
(n=2; 1%) and Paris (n=18; 5%). 46% of the cases had genetic testing (in 13% a final genetic 
diagnosis was made) and 43% a histopathology sample at the time of peer-review. Both were 
not required for review, but may be recommended by the reviewers. In 87% the initial 
diagnosis given by the submitting pediatric pneumologist, was confirmed by peer review 
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13
(Table 2). Among the 44 cases with their diagnosis altered by peer-review, the diagnosis 
was wrong in 27%, in 50% it was too general and in 23% significant information was added 
(Table 2, detailed cases Table S3). The re-specification of the diagnosis from peer-review in 
conditions categorized as chILD occurring primarily in infancy (“A” groups in table S3) was 
mainly due to knowledge from pathology review (20 of 44 cases) and genetics (7 cases), 
whereas in chILD conditions occurring at all ages (“B” groups in table S3) radiological 
imaging and clinical review had the biggest impact. The age distribution of the children peer-
reviewed had an initial peak in the first two years of life and an almost even distribution 
towards early adulthood (Fig. S3). Although changes in therapy were usually not 
recommended by peer-review, we observed changes made in the majority of cases with an 
altered diagnosis (Fig. 3, Table S3, last column).  
 Overall the spectrum of chILD categories and subcategories observed was broad, the 
majority of the patients coming from conditions more prevalent in infancy, i.e. categories A3 
and A4, and DPLD-related to systemic disease processes (Table 3). The times to peer review 
acceptance and to peer review completion was very variable, which was mainly due to the 
need to retrieve missing information and communication delays (Table 2). Some of the cases 
peer-reviewed entered the randomized controlled trial on hydroxychloroquine run by this 
platform (Online supplement). 
Ability of clinicians to subcategorize the final working diagnosis in the classification system 
used by the chILD-EU register 
 This was tested in a collection of 25 complex chILD cases. In the 1st round none of the 
cases was subcategorized correctly by any of the 9 experts, whereas in the second round and 
after training there was a significant improvement of correct categorization (Fig. 4, upper 
panel). The overall exact agreement of the nine experts in the 1st round was 59% (free 
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14
marginal kappa 0.19), and in the 2nd round 64%. This seems to be a relatively low inter-
rater agreement, however it must be considered that of the 225 (25x9) answers received for 
example in first round, a total of 54 were incorrect of which 23 (10% of all answers) resulted 
in allocation to a false category and 31 merely in a wrong subcategory.  
 The many other important lessons which we have learned during the project are listed 
in Table 4.
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DISCUSSION 
 Here we report details on the successful design and implementation of a web-based 
chILD management platform. We showed that it was feasible and practical to develop a 
European registry and biobank based for independent and multidisciplinary review of chILD, 
leading to protocolised follow-up and the setting up of randomized controlled trials. Our 
experiences may be a useful model for those setting up registries and biobanks across Europe 
in other fields. Specifically, we also detail the results on the sub-classification of chILD 
diagnoses, the consequences of peer reviewing and the spectrum of the cases accumulated 
over a three year period. 
 The chILD-EU project has linked national, European and international respiratory and 
general paediatricians, patients and parents groups, radiologists, pathologists, geneticists, 
translational and clinical scientists. The platform is an open resource for interested individuals 
and institutions. We have proposed diagnostic pathways of chILD [13] which were 
implemented here, and we have established and harmonized peer review to actively help 
participating physicians with the diagnosis and treatment of their cases. In 44 cases the 
diagnosis was altered by peer review and substantial changes in treatment were observed. 
 Making a correct and independently peer–reviewed final working diagnosis in rare 
diseases is of importance for several reasons. Firstly, the treating local physician may receive 
help or guidance during the diagnostic work up, which may translate into more appropriate 
treatment. Secondly, both the physician and the family are reassured; these conditions are so 
rare that even big centers will not see enough always to be confident, and sharing cases can 
increase expertise across Europe. This may have important psychosocial and prognostic 
consequences. Thirdly, for the register and biobank it is of great importance to have a reliable 
diagnosis and categorization, to allow specific long term follow up and ensure only children 
with an appropriate diagnosis are entered into randomized controlled trials. Here we have 
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organized for the first time an easily accessed system tapping in to international expertise 
and described the activities since inception. The biggest hurdle for peer review is the local site 
physician who frequently lacks the time and resources to complete cases which were partially 
submitted, as indicated by the 190 patients with insufficient data precluding the start of the 
peer review. Although for the majority of cases the initial working diagnosis was confirmed 
by peer reviewers there were significant changes of the final working diagnosis in nearly one 
in seven cases (Table S3), underpinning the pivotal role of peer review in pediatrics, as for 
adults with diffuse parenchymal lung disease [14]. Future studies will address the 
reproducibility and precision of making the working diagnosis in chILD by multidisciplinary 
pediatric teams.  
 Categorization and subcategorization of a diagnosis is of great importance for any 
systematic register. Based on our previous local assessment of the reliability in chILD diffuse 
parenchymal disease and an average correct rate of 87% [2], we were not surprised by the 
relatively low rate of correct categorization (72%) obtained from a large group of nine 
untrained experts. The number of cases put by individual reviewer into a wrong category was 
low (10%). Nevertheless, subcategorization a diagnosis is sometimes difficult and not only 
needs to be further harmonized but also practiced by the teams. 
 We are now studying the natural history of chILD patients and ill describe 
frequencies and variability of end-points such as clinical scoring, pulmonary exacerbations 
[15], medication usage, hospitalization rates, costs of care and quality of life; this would be 
impossible without this sort of platform. Importantly, we have commenced the first ever 
randomized, placebo-controlled interventions in chILD after overcoming all administrative 
hurdles in Germany and started to recruit peer-reviewed cases (www.childeu.net, online 
supplement). We have a unique collective experience and have learned many lessons in the 
day-to-day practicalities of running a register and biobank (Tab. 4). 
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17
Challenges of the study and in the future 
 chILD is difficult to study because nomenclature varies in a group of more than 200 
entities, all of which are rare. Although diffuse parenchymal disease may more correctly 
describe the entities included, we adopted the acronym chILD in line with the statement of the 
American Thoracic Society in 2013 [9]. The chILD-EU project introduced the term in Europe 
and increased the awareness of chILD. The interaction between professionals and family 
groups across Europe has perhaps been the most important result of this initiative. Also of 
importance is the support of the growing chILD-EU group by the European Respiratory 
Society (ERS) establishing a Clinical Research Collaboration (CRC) and the European Union 
by the COST Action CA16125. Long term follow of a large cohort of patients with chILD to 
learn about the natural history will be a major challenge in the future. Hurdles include access 
to funding to support clinicians faced with a big daily workload to ensure high quality data 
continues to be entered into the register. Furthermore, the large administrative hurdles are a 
major barrier to investigator-initiated studies in rare diseases in Europe (see Supplemental 
Discussion). 
 Taken together, the FP7 project chILD-EU has generated a solid basis for the 
comprehensive study of pediatric interstitial lung diseases. The platform is a stepping stone 
for future work. Many new tools were made available to improve the care of individual cases. 
Collectively data are generated to describe simple and complex end-points, medication usage, 
and some centers were opened to perform randomized placebo-controlled interventions in 
chILD. In the future, much more diverse activities are envisioned including basic and 
translational mechanistic studies, epidemiological investigations and teaching activities, all of 
which would be impossible without a central registry. 
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LEGENDS TO THE FIGURES 
 
Figure 1 
Management platform 
 
Figure 2 
Peer review process in the chILD-EU register. A) Upon peer review request by the local site 
physician, completeness of data is checked and if so, peer reviewers are selected and asked 
via emails from the system to start reviewing. The clinician peer reviewer prepares and 
presents the case in a common meeting, either in person, or web-based with shared screen in 
internationally composed multidisciplinary teams. After completion, the clinician peer 
reviewer generates a final peer reviewer (working) diagnosis and subcategorizes the 
diagnosis. The local site physician is informed via a mailing from the system about the 
conclusion of the review. B) Consort diagram detailing patient flow during peer review 
process. 
 
Figure 3 
Changes in therapy observed after peer review in those 44 patients in whom the diagnosis was 
altered by peer-review.  
 
Figure 4 
Selection of the correct subcategory from a panel of 5 suggestions each for 25 final 
working diagnoses by 9 experienced pediatric clinical peer reviewers (see also Table S2). 
The upper panel shows the correct reviewers by question 1 to 25 in the first and second 
round. The latter was done after training using a video tutorial, web-based email-discussion 
of open issues and a personal meeting. The lower panel shows the responses of the 
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individual peer reviewers before and after training. Responses of first and second round 
were compared by 2-sided paired t-test. The lower panel shows the responses of the 
individual peer reviewers before and after training.  
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Table 1 Number of subjects included with country indicated and peer reviews done (Status: 
31 November 2016) 
Country Number of subjects 
included with 
country indicated 
Country (%) Final peer review 
done (n ) 
Peer reviews 
done (%) 
Germany 243 42.3% 158 65.0% 
Italy 22 3.8% 10 45.5% 
Turkey 55 9.6% 47 85.5% 
UK 103 17.9% 65 63.1% 
France 41 7.1% 19 46.3% 
Belgium 4 0.7% 1 25.0% 
Brazil 2 0.3% 1 50.0% 
Croatia 1 0.2% 1 100% 
Denmark 9 1.6% 8 88.9% 
Netherlands 2 0.3% 1 50.0% 
Poland 28 4.9% 23 82.1% 
South Africa 3 0.5% 1 33.3% 
Spain 4 0.7% 2 50.0% 
Switzerland 7 1.2% 6 85.7% 
Austria 5 0.9% 1 20.0% 
Serbia/Montenegro 1 0.2% 0 0.0% 
not indicated 45 7.8% 2 4.4% 
All 575 100.0% 346 60.2% 
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Table 2 Results from the peer reviewing activities 
 Number of cases Percentage 
No change from initial diagnosis to peer-review 
diagnosis 
302 87% 
 
Change from initial diagnosis to peer-review 
diagnosis 
44 13% 
Initial diagnosis was wrong => corrected1 12 27% 
Initial diagnosis was too general => specified final 
diagnosis given2 
22 50% 
Initial diagnosis was incomplete => relevant 
information added3 
10 23% 
Time from Peer Review request until acceptance 
(days) 
Median, mean (range) 1; 30.5 (0 – 746) 
Time from Peer Review acceptance until 
completion (days) 
Median, mean (range) 37; 67.5 (0 – 803) 
 
Examples 1“Postinfectious bronchitis obliterans” was changed to “Neuroendocrine cell 
hyperplasia of infancy”; 2 “Interstitial lung disease“ was specified as “Cellular non-specific 
interstitial pneumonitis due to SFTPC mutation”; 3 “Alveolar capillary dysplasia without 
misalignment of the pulmonary veins” was changed to “Alveolar capillary dysplasia without 
misalignment of the pulmonary veins and associated pulmonary interstitial glycogenosis PIG” 
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Table 3 – Distribution of 346 subjects in the disease categories and subcategories of the chILD-EU register after peer review 
 
Category Subcategory / Diagnosis Total Percentage 
A1 - DPLD-Diffuse developmental disorders  9 2.6% 
 Alveolar capillary dysplasia with misalignment 
pulmonary vein 
7  
 Congenital alveolar dysplasia 2  
A2 - DPLD-Growth abnormalities deficient alveolarisation  22 6.4% 
 Related to preterm birth 11  
 Related to chromosomal disorders 8  
 Others 3  
A3 - DPLD-Infant conditions of undefined etiology  64 18.5% 
 Chronic tachypnea of infancy (usual or aberrant)  30  
 Neuroendocrine cell hyperplasia of infancy  27  
 Pulmonary interstitial glycogenosis 5  
 Others 2  
A4 - DPLD–related to alveolar surfactant region  77 22.3% 
 ABCA3-Mutations 18  
 SFTPC-Mutation 10  
 NKX2.1-Mutations 3  
 Non-specific interstitial pneumonitis (NSIP) 19  
 Pulmonary alveolar proteinosis (PAP) 9  
 Others 18  
Ax - DPLD-unclear RDS in the mature neonate  5 1.4% 
Ay - DPLD-unclear RDS in the almost (30-36 wks) mature neonate  9 2.6% 
B1 - DPLD-related to systemic disease processes  54 15.6% 
 Sarcoidosis 12  
 Idiopathic pulmonary hemosiderosis 6  
 Storage diseases 4  
 Immune-mediated/collagen vascular disorders 4  
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 Familial dysautonomia 3  
 Filamin A Mutation 3  
 Langerhans cell histiocytosis 3  
 GPA – Granulomatosis with polyangiitis (Wegener) 3  
 Others 16  
B2 - DPLD-in the presumed immune intact host, related to exposures 
(infectious/non-infectious) 
 46 13.3% 
 Infectious/post-infectious processes 17  
 Bronchiolitis obliterans 14  
 Exogen allergic alveolitis/hypersensitivity pneumonitis 7  
 Others 8  
B3 - DPLD-in the immunocompromised host or transplanted  15 4.3% 
 NSIP 4  
 Bronchiolitis obliterans (BO) 3  
 Related to transplantation and rejection 3  
 Others 5  
B4 - DPLD-related to lung vessels structural processes  16 4.6% 
 Pulmonary hemorrhage 8  
 Pulmonary hypertension 5  
 Others 3  
B5 - DPLD-related to reactive lymphoid lesions  4 1.2% 
 Lymphocytic interstitial pneumonia (LIP) 3  
 Others 1  
Bx - DPLD-unclear RDS in the NON-neonate  1 0.3% 
By - DPLD-unclear NON-neonate  5 1.4% 
Bz - DPLD  1 0.3% 
C1 - Localized, congenital gross structural abnormalities of the lungs  6 1.7% 
C2 – Localized, acquired gross structural abnormalities of the lungs  0 0% 
D - Airway disorders  12 3.5% 
 Chronic Bronchitis 7  
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 Others 5  
DPLD - Diffuse parenchymal lung diseases; RDS – Respiratory distress syndrome. Cases of chronic tachypnea of infancy (usual or aberrant) had no 
biopsy and were defined as described previously [16]; cases were only labelled “Neuroendocrine cell hyperplasia of infancy” if there was proof by 
biopsy and concordant clinical symptoms. Details on the classification system and definitions used are given in the supplement of Griese et al 2015 
[12]. 
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Table 4 – Practical advice from lessons learned during work with the management platform 
All participants 
• Do not start peer review until all necessary information and materials on a case are 
collected 
• Do not expect even after training that ability to work with the database is sustained 
without participants using it regularly 
• Strictly keep communication on cases within the management platform 
• Training in relatively complex procedures like uploading imaging should only be 
done in central / national sites, as technical details to be solved (for example, hospital 
firewalls) may otherwise be too time-consuming.  
• Plan extensive time for local ethics applications and other local center processes if a 
randomized controlled trial is contemplated 
• Practical support to enter data should be supplied centrally including upload of 
imaging, digitizing of letters, cutting of wax blocks, staining slides, upload of scans, 
shared screen guided support lessons, double entry of quality of life and other 
questionnaires, etc.  
Peer reviewer / national coordinator 
• Organization of regular local conference sessions using active cases 
• Explanation and exercises using the categorization system 
Data manager and auditing staff 
• Build a personal relation with site staff 
• Always offer training and help regarding all aspects of the register 
• Constantly collect, document and optimize (screenshot, explanation, suggested 
solutions) problems faced when working with the database 
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ABSTRACT 
Children´s interstitial lung diseases (chILD) cover many rare entities, frequently not 
diagnosed or studied in detail. There is a great need for specialized advice and for 
internationally agreed sub-classification of entities collected in a register. 
Our objective was to implement an international management platform with 
independent multidisciplinary review of cases at presentation for long term follow up and to 
test if this would allow for more accurate diagnosis. Also quality and reproducibility of a 
diagnostic sub-classification system were assessed using a collection of 25 complex chILD 
cases. 
A web-based chILD management platform with a registry and biobank was 
successfully designed and implemented. Over a three-year period 575 patients were included 
for observation spanning a wide spectrum of chILD. In 346 patients multidisciplinary reviews 
were completed by teams at 5 international sites (Munich 51%, London 12%, Hannover 31%, 
Ankara 1% and Paris 5%). In 13% the diagnosis reached by the referring team was not 
confirmed by peer review. Among these, the diagnosis initially given was wrong (27%), 
imprecise (50%) or significant information was added (23%).  
The ability of nine expert clinicians to sub-categorize the final diagnosis into the 
chILD-EU register classification had an overall exact inter-rater agreement of 59% on first 
assessment and after training, 64%. Only 10% of the ‘wrong’ answers resulted in allocation to 
an incorrect category. Sub-categorization proved useful but training is needed for optimal 
implementation. 
 We have shown that chILD-EU has generated a platform to help the clinical 
assessment of chILD. 
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Short summary 
What is the key question? 
Can an international management platform for children´s interstitial lung disease (chILD) 
with independent multidisciplinary review be implemented and is the diagnostic sub-
classification reproducible? 
 
What is the bottom line? 
Well-functioning, web-based multi-disciplinary teams were successfully set up, and 
significantly changed 13% of the diagnoses submitted by pediatric pneumologists. Sub-
classification by review-teams proved useful and although training in implementation is 
needed. 
 
Why read on? 
So you can learn how the system works and use it in the future. 
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INTRODUCTION 
Children´s interstitial lung diseases (chILD) is an umbrella term covering many rare 
conditions, frequently not diagnosed because the presentation is non-specific; and many 
entities which are ill- defined or poorly studied. Chest imaging shows diffuse abnormalities 
and age-appropriate lung function tests are abnormal. The incidence of these rare diseases in 
Europe is 0.5 to 1 cases in 100.000. In the United Kingdom and Ireland prevalence was 
estimated as 3.6 per million children [1], and in Germany at 1.32 new cases per 1 million 
children/year [2]. Prevalence and incidence is likely greatly under-estimated due to 
misdiagnosis, lack of an ICD code allowing hospital based estimates of cases, and the absence 
of a common register. Extrapolation to Europe (about 500 million people, 80 million children 
< 14 years) suggests there are about 2000 known cases and an incident case rate of more than 
100 per year. The overall mortality in childhood is around 15% [2]. There are no evidence 
based treatments for any of the diseases [3]. 
 The experiences of physicians, as well as the relatives and the patients, who often have 
been through a real diagnostic odyssey, show that these patients often do not receive optimal 
care [4]. Progress is also very slow because of lack of technical resources for obtaining 
second opinions in complex individual cases and the absence of the sort of large, well-
characterized cohorts which are essential for the conduct of randomized clinical trials. In 
pediatric oncology similar problems were solved decades ago as registries for diagnosis, 
systematic treatment plans and sufficient financial support were established [5]. In pediatric 
respiratory medicine cystic fibrosis has led the way from simple registries to the establishment 
of clinical trial networks [6]. Networks have also been established for primary ciliary 
dyskinesia [7].  
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36
 In chILD there is a pressing need for both specialized diagnostic advice from 
international experts because of the rareness of individual diagnoses, and services to provide 
local care and therapy. Our objective was to implement an international management platform 
with independent multidisciplinary review of cases at presentation for long term follow up, to 
test if this would allow for more accurate diagnosis and thus provide structures for 
randomized controlled trials of treatment and translational studies. We here describe how we 
made such a platform and the chILD cases accumulated over a three-year period. The 
outcomes from an expert review process are reported, together with assessment of the intra-
observer consistency of expert reviewers, to help identify training requirements for clinical 
experts. We intend that this report will serve as a model for others setting up registries and 
biobanks across Europe in other diseases and disciplines. 
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METHODS 
Rationale and need for the chILD register 
 The international registry for chILD was established to fill the previously unmet need 
of an i ternational platform to systematically collect data from pediatric patients and allows 
all groups of professional and private stakeholders to participate in the care of chILD patients. 
The registry governance fulfils the widely varying legal, data protection and ethical 
requirements across Europe, without compromising access to the data. 
Eligibility criteria, consent and ethical approval 
 Patients are identified by their local physicians, who can register as participants in a 
referring center. Any referring center needs to ensure compliance with all necessary 
contractual legal and ethical requirements. The central register support team assists 
throughout this process. Each patient and/or care giver gave respectively age appropriate 
assent and written informed consent before any data were entered. The register and biobank 
study was approved by the responsible external lead ethics board, the Ethical Review 
Committee of the Ludwig-Maximilians University Munich, Germany (EK 111-13). The data 
safety protection processes of the register and biobank was approved by the Telematic 
Platform (TMF), an organization for networked medical research.  
 chILD was defined as entities originating from abnormalities of components of the 
lung parenchyma, which include the alveolar epithelium, vascular endothelium, interposed 
connective tissues and more centrally, the peribronchiolar and peribronchial tissues; airways 
may be involved as a secondary process [8]. chILD was suspected if there were (1) respiratory 
symptoms/signs such as cough, tachy- or dyspnea at rest or with exercise, crackles, 
retractions, clubbing, failure to thrive, respiratory failure, (2) systemic arterial hypoxemia, (3) 
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diffuse radiological abnormalities, and if both feasible and available (4) abnormalities in 
pulmonary function testing, usually for a minimum duration of 4 weeks, but shorter in cases 
of acute severe chILD (usually neonatal onset), in accord with standard practice  [9, 10]. We 
included all suspected chILD [11]. A case not confirmed as chILD after peer review could be 
followed as a disease control. All patients included were prospectively and longitudinally 
followed. Baseline was the time of inclusion into the register; both prevalent cases which 
were already under review at the inception of the platform, as well as incident, newly 
diagnosed cases, were followed. During follow-up, suitable chILD patients in the register 
study were eligible to enter randomized controlled trials set up in the Secutrial® database, if 
consent was given. 
Minimal data set and workflows of operation 
 Cases were entered into the register using minimal dataset (generation and data base 
dictionary see online supplement and Tab. S1), peer-reviewed, categorized [12] and followed 
over time. Automatic reminders were sent if follow up was due. Communication on cases was 
strictly within the database using a discussion tool automatically embedding the local 
physician, the peer reviewers and additional experts if wished, in order to pool information 
without compromising security.  
Data safety concept, data base and biobank 
 In accord with best practice data protection (http://www.tmf-
ev.de/EnglishSite/Home.aspx), there is an institutionally and organizationally separated 
storage of identifying (IDAT) and medical data (MDAT)(Supplement Fig. S1). The 
processing of the pseudonymized medical data is using SecuTrial®, which is US Food and 
Drug Administration (FDA)-compliant and is concordant with good clinical practice rules 
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(GCP). An additional SecuTrial®-database for managing biomaterials is the central 
biobank at Munich University Hospital (Supplement Fig. S2).  
Quality control 
 The register manager and register physicians carefully audit data completeness and 
score the quality of imaging and histological studies. Early in the project, the standards 
working group generated consensus-agreed diagnostic and management clinical guidelines 
[13]. Due to shortage of resources, no source data verification is currently in place. In addition 
to immediate individual feedback to the centers via the national coordinator, annual reports 
are generated for each center and the register.  
Peer review 
 A central novel element of the register was the involvement of a multidisciplinary team 
review board. Although this is routine in adult ILD [14], until now this has not been routine in 
Europe in chILD. The goal of peer review was to give advice on diagnosis and differential 
diagnosis, to insure adherence to diagnostic standards set previously [13], to have a case 
review independent of the submitting center, to use a harmonized categorization system [12] 
and to come up with a final working diagnosis. Peer review teams were composed of a 
respiratory paediatrician, a paediatric radiologist and pathologist; if necessary a geneticist was 
also consulted. The teams were constituted first on a national basis to establish the workflow 
within the management platform and then rolled out as an international resource. For online 
training Skype conferences with shared screen features were organized. Peer review was 
started as soon as all relevant clinical data, imaging (see online supplement) and histology 
glass slides were available for the reviewers.  
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 To assess the skills of categorization of the final working diagnosis by clinicians, 
we randomly selected 25 chILD cases (from the first 312 cases peer-reviewed) with a 
pulmonary and non-pulmonary diagnosis to be allocated to one of five given subcategories 
(Tab. S2). The correct selection was determined by a group of three pediatric pneumologists 
who were very familiar with the categorization system and strictly adhered to the previously 
set up categorization rules [12]. The test took about 30 to 45 minutes. Nine pediatric 
pneumologists with long standing experience and interests in chILD were asked to 
subcategorize, and this test was repeated after 3 months. In between, a video and interactive 
training “How to categorize chILD” was used for teaching. 
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RESULTS  
Register design – how the chILD-EU management platform works 
 After registration of the local physician, an educational and interactive training session 
is undertaken. When familiar with the system, the physician or coordinator enters the web-
based site to set up a new patient and enter the minimal data set necessary for peer review. 
This includes a structured referral letter and imaging. Individual support for data entry by the 
central registry is offered. Great care is taken to pseudonymise uploaded letters and reports, 
and radiological images are automatically pseudonymised during upload (Fig. S1). 
 Baseline data includes the entire past clinical course of the patient until entry into the 
data base (Fig 1, left column). chILD-specific patient reported outcomes were developed and 
validated, and together with developmentally adapted versions for different age groups now 
available on the chILD platform in different languages (details see online supplement), as is 
information on health-economic status. Data obtained on a single occasion, such as biopsy, 
lavage and genetics, and prospective observations of specific treatments are entered separately 
(Fig 1, right column). Information is exchanged and saved between local physician, data 
manager and peer reviewer via emails dispatched from the system and a discussion panel. 
Following review, diagnosis and categorization (see below), the patient is observed 
prospectively over time with entry of a limited dataset (Fig 1, middle column).  
 Material sent for central biobanking is indicated in the patient data set with a 
collection number, so that local physician can track material associated with each subject. Site 
staff at central biobank record what has been sent with a collection identifier, so they can 
track materials. Biomaterials are entered into the separately run biobank. The material 
remains the property of the patient and/or family all the time. 
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Enrolment and demography 
 From January 2014 to November 2016 575 patients (53% male) from 82 centres in 16 
countries were enrolled in the database (Table 1). The median age of the children at inclusion 
was 5.5 years (range 0 to 25; mean 7.0, SD 6.3) with an almost even distribution over time.  
Peer review of cases to establish final working diagnosis, disease category and subcategory 
 When a peer review has been requested, the national coordinating team receives a 
message with an embedded link to the case, checks for completeness of data and materials, 
and decides if the review process can be started or not (Fig. 2A). During the review meeting, 
the clinician presents the case using the referral letter; the images are demonstrated by the 
radiologists and the pathological review when relevant material is available is also presented. 
When needed genetic advice is also taken. After discussion the lead clinician summarizes the 
diagnosis, categorizes the case and concludes the peer review. An automatic message informs 
the site physician about the result and further recommendations.  
Results from peer reviewing by multidisciplinary review teams 
 Of the 575 patients included into the register for observation, 190 patients had 
insufficient data precluding the start of the peer review. In 385 patients peer review requests 
were accepted, 39 could not be finalized due to information for which the reviewers asked but 
was not forthcoming (Fig. 2B), and a total of 346 peer reviews completed. These were done 
by teams in Munich (n=176; 51%), London (n=43, 12%), Hannover (n=107, 31%), Ankara 
(n=2; 1%) and Paris (n=18; 5%). 46% of the cases had genetic testing (in 13% a final genetic 
diagnosis was made) and 43% a histopathology sample at the time of peer-review. Both were 
not required for review, but may be recommended by the reviewers. In 87% the initial 
diagnosis given by the submitting pediatric pneumologist, was confirmed by peer review 
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(Table 2). Among the 44 cases with their diagnosis altered by peer-review, the diagnosis 
was wrong in 27%, in 50% it was too general and in 23% significant information was added 
(Table 2, detailed cases Table S3). The re-specification of the diagnosis from peer-review in 
conditions categorized as chILD occurring primarily in infancy (“A” groups in table S3) was 
mainly due to knowledge from pathology review (20 of 44 cases) and genetics (7 cases), 
whereas in chILD conditions occurring at all ages (“B” groups in table S3) radiological 
imaging and clinical review had the biggest impact. The age distribution of the children peer-
reviewed had an initial peak in the first two years of life and an almost even distribution 
towards early adulthood (Fig. S3). Although changes in therapy were usually not 
recommended by peer-review, we observed changes made in the majority of cases with an 
altered diagnosis (Fig. 3, Table S3, last column).  
 Overall the spectrum of chILD categories and subcategories observed was broad, the 
majority of the patients coming from conditions more prevalent in infancy, i.e. categories A3 
and A4, and DPLD-related to systemic disease processes (Table 3). The times to peer review 
acceptance and to peer review completion was very variable, which was mainly due to the 
need to retrieve missing information and communication delays (Table 2). Some of the cases 
peer-reviewed entered the randomized controlled trial on hydroxychloroquine run by this 
platform (Online supplement). 
Ability of clinicians to subcategorize the final working diagnosis in the classification system 
used by the chILD-EU register 
 This was tested in a collection of 25 complex chILD cases. In the 1st round none of the 
cases was subcategorized correctly by any of the 9 experts, whereas in the second round and 
after training there was a significant improvement of correct categorization (Fig. 4, upper 
panel). The overall exact agreement of the nine experts in the 1st round was 59% (free 
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marginal kappa 0.19), and in the 2nd round 64%. This seems to be a relatively low inter-
rater agreement, however it must be considered that of the 225 (25x9) answers received for 
example in first round, a total of 54 were incorrect of which 23 (10% of all answers) resulted 
in allocation to a false category and 31 merely in a wrong subcategory.  
 The many other important lessons which we have learned during the project are listed 
in Table 4.
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DISCUSSION 
 Here we report details on the successful design and implementation of a web-based 
chILD management platform. We showed that it was feasible and practical to develop a 
European registry and biobank based for independent and multidisciplinary review of chILD, 
leading to protocolised follow-up and the setting up of randomized controlled trials. Our 
experiences may be a useful model for those setting up registries and biobanks across Europe 
in other fields. Specifically, we also detail the results on the sub-classification of chILD 
diagnoses, the consequences of peer reviewing and the spectrum of the cases accumulated 
over a three year period. 
 The chILD-EU project has linked national, European and international respiratory and 
general paediatricians, patients and parents groups, radiologists, pathologists, geneticists, 
translational and clinical scientists. The platform is an open resource for interested individuals 
and institutions. We have proposed diagnostic pathways of chILD [13] which were 
implemented here, and we have established and harmonized peer review to actively help 
participating physicians with the diagnosis and treatment of their cases. In 44 cases the 
diagnosis was altered by peer review and substantial changes in treatment were observed. 
 Making a correct and independently peer–reviewed final working diagnosis in rare 
diseases is of importance for several reasons. Firstly, the treating local physician may receive 
help or guidance during the diagnostic work up, which may translate into more appropriate 
treatment. Secondly, both the physician and the family are reassured; these conditions are so 
rare that even big centers will not see enough always to be confident, and sharing cases can 
increase expertise across Europe. This may have important psychosocial and prognostic 
consequences. Thirdly, for the register and biobank it is of great importance to have a reliable 
diagnosis and categorization, to allow specific long term follow up and ensure only children 
with an appropriate diagnosis are entered into randomized controlled trials. Here we have 
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organized for the first time an easily accessed system tapping in to international expertise 
and described the activities since inception. The biggest hurdle for peer review is the local site 
physician who frequently lacks the time and resources to complete cases which were partially 
submitted, as indicated by the 190 patients with insufficient data precluding the start of the 
peer review. Although for the majority of cases the initial working diagnosis was confirmed 
by peer reviewers there were significant changes of the final working diagnosis in nearly one 
in seven cases (Table S3), underpinning the pivotal role of peer review in pediatrics, as for 
adults with diffuse parenchymal lung disease [14]. Future studies will address the 
reproducibility and precision of making the working diagnosis in chILD by multidisciplinary 
pediatric teams.  
 Categorization and subcategorization of a diagnosis is of great importance for any 
systematic register. Based on our previous local assessment of the reliability in chILD diffuse 
parenchymal disease and an average correct rate of 87% [2], we were not surprised by the 
relatively low rate of correct categorization (72%) obtained from a large group of nine 
untrained experts. The number of cases put by individual reviewer into a wrong category was 
low (10%). Nevertheless, subcategorization a diagnosis is sometimes difficult and not only 
needs to be further harmonized but also practiced by the teams. 
 We are now studying the natural history of chILD patients and ill describe 
frequencies and variability of end-points such as clinical scoring, pulmonary exacerbations 
[15], medication usage, hospitalization rates, costs of care and quality of life; this would be 
impossible without this sort of platform. Importantly, we have commenced the first ever 
randomized, placebo-controlled interventions in chILD after overcoming all administrative 
hurdles in Germany and started to recruit peer-reviewed cases (www.childeu.net, online 
supplement). We have a unique collective experience and have learned many lessons in the 
day-to-day practicalities of running a register and biobank (Tab. 4). 
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Challenges of the study and in the future 
 chILD is difficult to study because nomenclature varies in a group of more than 200 
entities, all of which are rare. Although diffuse parenchymal disease may more correctly 
describe the entities included, we adopted the acronym chILD in line with the statement of the 
American Thoracic Society in 2013 [9]. The chILD-EU project introduced the term in Europe 
and increased the awareness of chILD. The interaction between professionals and family 
groups across Europe has perhaps been the most important result of this initiative. Also of 
importance is the support of the growing chILD-EU group by the European Respiratory 
Society (ERS) establishing a Clinical Research Collaboration (CRC) and the European Union 
by the COST Action CA16125. Long term follow of a large cohort of patients with chILD to 
learn about the natural history will be a major challenge in the future. Hurdles include access 
to funding to support clinicians faced with a big daily workload to ensure high quality data 
continues to be entered into the register. Furthermore, the large administrative hurdles are a 
major barrier to investigator-initiated studies in rare diseases in Europe (see Supplemental 
Discussion). 
 Taken together, the FP7 project chILD-EU has generated a solid basis for the 
comprehensive study of pediatric interstitial lung diseases. The platform is a stepping stone 
for future work. Many new tools were made available to improve the care of individual cases. 
Collectively data are generated to describe simple and complex end-points, medication usage, 
and some centers were opened to perform randomized placebo-controlled interventions in 
chILD. In the future, much more diverse activities are envisioned including basic and 
translational mechanistic studies, epidemiological investigations and teaching activities, all of 
which would be impossible without a central registry. 
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LEGENDS TO THE FIGURES 
 
Figure 1 
Management platform 
 
Figure 2 
Peer review process in the chILD-EU register. A) Upon peer review request by the local site 
physician, completeness of data is checked and if so, peer reviewers are selected and asked 
via emails from the system to start reviewing. The clinician peer reviewer prepares and 
presents the case in a common meeting, either in person, or web-based with shared screen in 
internationally composed multidisciplinary teams. After completion, the clinician peer 
reviewer generates a final peer reviewer (working) diagnosis and subcategorizes the 
diagnosis. The local site physician is informed via a mailing from the system about the 
conclusion of the review. B) Consort diagram detailing patient flow during peer review 
process. 
 
Figure 3 
Changes in therapy observed after peer review in those 44 patients in whom the diagnosis was 
altered by peer-review.  
 
Figure 4 
Selection of the correct subcategory from a panel of 5 suggestions each for 25 final 
working diagnoses by 9 experienced pediatric clinical peer reviewers (see also Table S2). 
The upper panel shows the correct reviewers by question 1 to 25 in the first and second 
round. The latter was done after training using a video tutorial, web-based email-discussion 
of open issues and a personal meeting. The lower panel shows the responses of the 
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individual peer reviewers before and after training. Responses of first and second round 
were compared by 2-sided paired t-test. The lower panel shows the responses of the 
individual peer reviewers before and after training.  
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Table 1 Number of subjects included with country indicated and peer reviews done (Status: 
31 November 2016) 
Country Number of subjects 
included with 
country indicated 
Country (%) Final peer review 
done (n ) 
Peer reviews 
done (%) 
Germany 243 42.3% 158 65.0% 
Italy 22 3.8% 10 45.5% 
Turkey 55 9.6% 47 85.5% 
UK 103 17.9% 65 63.1% 
France 41 7.1% 19 46.3% 
Belgium 4 0.7% 1 25.0% 
Brazil 2 0.3% 1 50.0% 
Croatia 1 0.2% 1 100% 
Denmark 9 1.6% 8 88.9% 
Netherlands 2 0.3% 1 50.0% 
Poland 28 4.9% 23 82.1% 
South Africa 3 0.5% 1 33.3% 
Spain 4 0.7% 2 50.0% 
Switzerland 7 1.2% 6 85.7% 
Austria 5 0.9% 1 20.0% 
Serbia/Montenegro 1 0.2% 0 0.0% 
not indicated 45 7.8% 2 4.4% 
All 575 100.0% 346 60.2% 
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Table 2 Results from the peer reviewing activities 
 Number of cases Percentage 
No change from initial diagnosis to peer-review 
diagnosis 
302 87% 
 
Change from initial diagnosis to peer-review 
diagnosis 
44 13% 
Initial diagnosis was wrong => corrected1 12 27% 
Initial diagnosis was too general => specified final 
diagnosis given2 
22 50% 
Initial diagnosis was incomplete => relevant 
information added3 
10 23% 
Time from Peer Review request until acceptance 
(days) 
Median, mean (range) 1; 30.5 (0 – 746) 
Time from Peer Review acceptance until 
completion (days) 
Median, mean (range) 37; 67.5 (0 – 803) 
 
Examples 1“Postinfectious bronchitis obliterans” was changed to “Neuroendocrine cell 
hyperplasia of infancy”; 2 “Interstitial lung disease“ was specified as “Cellular non-specific 
interstitial pneumonitis due to SFTPC mutation”; 3 “Alveolar capillary dysplasia without 
misalignment of the pulmonary veins” was changed to “Alveolar capillary dysplasia without 
misalignment of the pulmonary veins and associated pulmonary interstitial glycogenosis PIG” 
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Table 3 – Distribution of 346 subjects in the disease categories and subcategories of the chILD-EU register after peer review 
 
Category Subcategory / Diagnosis Total Percentage 
A1 - DPLD-Diffuse developmental disorders  9 2.6% 
 Alveolar capillary dysplasia with misalignment 
pulmonary vein 
7  
 Congenital alveolar dysplasia 2  
A2 - DPLD-Growth abnormalities deficient alveolarisation  22 6.4% 
 Related to preterm birth 11  
 Related to chromosomal disorders 8  
 Others 3  
A3 - DPLD-Infant conditions of undefined etiology  64 18.5% 
 Chronic tachypnea of infancy (usual or aberrant)  30  
 Neuroendocrine cell hyperplasia of infancy  27  
 Pulmonary interstitial glycogenosis 5  
 Others 2  
A4 - DPLD–related to alveolar surfactant region  77 22.3% 
 ABCA3-Mutations 18  
 SFTPC-Mutation 10  
 NKX2.1-Mutations 3  
 Non-specific interstitial pneumonitis (NSIP) 19  
 Pulmonary alveolar proteinosis (PAP) 9  
 Others 18  
Ax - DPLD-unclear RDS in the mature neonate  5 1.4% 
Ay - DPLD-unclear RDS in the almost (30-36 wks) mature neonate  9 2.6% 
B1 - DPLD-related to systemic disease processes  54 15.6% 
 Sarcoidosis 12  
 Idiopathic pulmonary hemosiderosis 6  
 Storage diseases 4  
 Immune-mediated/collagen vascular disorders 4  
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 Familial dysautonomia 3  
 Filamin A Mutation 3  
 Langerhans cell histiocytosis 3  
 GPA – Granulomatosis with polyangiitis (Wegener) 3  
 Others 16  
B2 - DPLD-in the presumed immune intact host, related to exposures 
(infectious/non-infectious) 
 46 13.3% 
 Infectious/post-infectious processes 17  
 Bronchiolitis obliterans 14  
 Exogen allergic alveolitis/hypersensitivity pneumonitis 7  
 Others 8  
B3 - DPLD-in the immunocompromised host or transplanted  15 4.3% 
 NSIP 4  
 Bronchiolitis obliterans (BO) 3  
 Related to transplantation and rejection 3  
 Others 5  
B4 - DPLD-related to lung vessels structural processes  16 4.6% 
 Pulmonary hemorrhage 8  
 Pulmonary hypertension 5  
 Others 3  
B5 - DPLD-related to reactive lymphoid lesions  4 1.2% 
 Lymphocytic interstitial pneumonia (LIP) 3  
 Others 1  
Bx - DPLD-unclear RDS in the NON-neonate  1 0.3% 
By - DPLD-unclear NON-neonate  5 1.4% 
Bz - DPLD  1 0.3% 
C1 - Localized, congenital gross structural abnormalities of the lungs  6 1.7% 
C2 – Localized, acquired gross structural abnormalities of the lungs  0 0% 
D - Airway disorders  12 3.5% 
 Chronic Bronchitis 7  
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 Others 5  
DPLD - Diffuse parenchymal lung diseases; RDS – Respiratory distress syndrome. Cases of chronic tachypnea of infancy (usual or aberrant) had no 
biopsy and were defined as described previously [16]; cases were only labelled “Neuroendocrine cell hyperplasia of infancy” if there was proof by 
biopsy and concordant clinical symptoms. Details on the classification system and definitions used are given in the supplement of Griese et al 2015 
[12]. 
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60
Table 4 – Practical advice from lessons learned during work with the management platform 
All participants 
• Do not start peer review until all necessary information and materials on a case are 
collected 
• Do not expect even after training that ability to work with the database is sustained 
without participants using it regularly 
• Strictly keep communication on cases within the management platform 
• Training in relatively complex procedures like uploading imaging should only be 
done in central / national sites, as technical details to be solved (for example, hospital 
firewalls) may otherwise be too time-consuming.  
• Plan extensive time for local ethics applications and other local center processes if a 
randomized controlled trial is contemplated 
• Practical support to enter data should be supplied centrally including upload of 
imaging, digitizing of letters, cutting of wax blocks, staining slides, upload of scans, 
shared screen guided support lessons, double entry of quality of life and other 
questionnaires, etc.  
Peer reviewer / national coordinator 
• Organization of regular local conference sessions using active cases 
• Explanation and exercises using the categorization system 
Data manager and auditing staff 
• Build a personal relation with site staff 
• Always offer training and help regarding all aspects of the register 
• Constantly collect, document and optimize (screenshot, explanation, suggested 
solutions) problems faced when working with the database 
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Management platform  
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Peer review process in the chILD-EU register. A) Upon peer review request by the local site physician, 
completeness of data is checked and if so, peer reviewers are selected and asked via emails from the 
system to start reviewing. The clinician peer reviewer prepares and presents the case in a common meeting, 
either in person, or web-based with shared screen in internationally composed multidisciplinary teams. After 
completion, the clinician peer reviewer generates a final peer reviewer (working) diagnosis and 
subcategorizes the diagnosis. The local site physician is informed via a mailing from the system about the 
conclusion of the review. B) Consort diagram detailing patient flow during peer review process.  
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Changes in therapy observed after peer review in those 44 patients in whom the diagnosis was altered by 
peer-review.  
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Selection of the correct subcategory from a panel of 5 suggestions each for 25 final working diagnoses by 9 
experienced pediatric clinical peer reviewers (see also Table S2). The upper panel shows the correct 
reviewers by question 1 to 25 in the first and second round. The latter was done after training using a video 
tutorial, web-based email-discussion of open issues and a personal meeting. The lower panel shows the 
responses of the individual peer reviewers before and after training. Responses of first and second round 
were compared by 2-sided paired t-test. The lower panel shows the responses of the individual peer 
reviewers before and after training.  
 
249x430mm (300 x 300 DPI)  
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Methods 
 
Brief history 
 The nucleus for this project was a long-standing scientific cooperation of the 
participants in the European Respiratory Society chILD-working group, which works in close 
cooperation with the US and Australasian chILD working groups. The award of the chILD-
EU (FP7-305653) project (December 2012 to November 2016) stimulated the initiation of this 
international platform, starting with 10 academic partners from 5 European countries and now 
including more than 80 clinical sites. 
Generation of items of the minimal data set and workflows of operation 
 Consensus about the minimal data set necessary for a sufficiently in-depth description 
of chILD cases was obtained on the basis of the experience with the GOLDnet pediatric 
database of the kids lung register, the French Respirare system and the US-chILD database, 
which were all in a state of development around 2012. For each variable compromises were 
generated by the chILD experts and support groups during two 2-day face-to-face meetings 
and many web-based conferences, balancing the workload needed to enter data and the need 
for comprehensive information. A concise minimal data set was established and is appended 
as Supplemental Table S1. The structure of the registry was organized to reflect the workflow 
of baseline data collection, peer review, data collected only once and that collected repeatedly 
during the observation of the course of the disease, as newly diagnosed (incident, 4, 8, 12 
weeks, 6 months, annually) or cases already known to the center (prevalent, 6 months, 
annually). Peer review was started, when necessary clinical data, imaging and (where 
relevant) histology slides were available for the reviewers. Cases were then followed over 
time; the newly diagnosed incident cases at 4, 8, 12 weeks, 6 months, then annually; cases 
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already known to the center, i.e. prevalent cases were re-studied after 6 months and then 
annually.  
Data safety concept, data base and biobank 
 The data protection concept of the European management platform for children´s 
interstitial lung disease register (chILD-EU) is based on the generic data protection concepts 
of the Technologie- und Methodenplattform für die vernetzte medizinische Forschung e.V. 
(TMF) for the provision of treatment and research data in clinically focused research centers 
(http://www.tmf-ev.de/EnglishSite/Home.aspx). The Kids Lung Register (KLR) e.V. is 
responsible for processing and storing data and biomaterials. An internationally agreed patient 
information and consent form was translated into different European languages. Signed 
consent and age-appropriate assent when relevant for each patient and/or their legal parental 
representatives is obtained by the attending physician, and is a prerequisite for inclusion. 
Patients may at any time withdraw access rights to his or data or deletion of the data or 
biomaterials. The Philipps-University Marburg (PUM) and a separate institution, the 
University of Giessen Institut für medizinische Biometrie, Epidemiologie und Informatik are 
respectively responsible for medical data storage (MDAT) and processing and for storage of 
the central list of patients for identifying data (IDAT). This institutionally and 
organizationally separated storage of identifying (IDAT) and medical data (MDAT)(Fig. S1) 
is achieved using independent system administrators. The MDAT is hosted under the 
responsibility of PUM in the high security center of T-Systems in Nürnberg, Germany, 
administered and monitored by IMotion, Fürth on behalf of PUM. The collaboration between 
the PMU and the University of Giessen is contractual with a written agreement that specifies 
the complete independence of University of Giessen from any authority. 
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 The processing of MDAT is based on the portal solution SecuTrial®, already proven 
in many other medical research projects and provided to the participants at their local sites via 
usage over the internet within a web browser. It is Food and Drug Administration (FDA)-
compliant and is compliant with basic good clinical practice (GCP). The platform is provided 
and licensed by the Central Information Office at Philipps-Universität Marburg. For 
pseudonymization the study database has an interface to a central list of patients that holds the 
identifying data and the corresponding patient ID (PID) which is returned to the study 
database when a new request for patient entry is made. All CT images were available as 
during upload automatically pseudonomized DICOM files which were downloaded in zipped 
format from the SecuTrial® web-based system and viewed on local work stations with the 
help of Syngo fastview (Siemens, Munich, Germany). An additional secuTrial®-database for 
managing the biomaterials collected by and sent from participating centers is provided for the 
central biobank at Munich University Hospital (Fig. S2). The biomaterial management 
database is neither connected to the central patient list nor to the medical study database and 
does not contain data to track back to an individual patient. It holds information about the 
storage location and condition of biological samples identified by its own unique biomaterial 
collection-ID for each sample. It cannot track back to the individual patient. The study and 
biomaterial management databases are implemented with the technical core components of 
secuTrial® based on the following components: LINUX as the operating system for database 
and web server, ORACLE as database server, WebObjects Application Server Java as a 
server-side programming language, HTML and JavaScript within the web browser on the 
client computers, and fully encrypted data transfer protocol using SSL. Access to all MDAT 
and all biomaterial management data are completely logged within a system-integrated audit-
trail. Meticulous attention to data handling ensuring compliance with EU regulation was an 
important, albeit very time-consuming, part of the project. 
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Outcome parameters 
 The clinical and biological relevance and feasibility of outcomes commonly used in 
clinical practice were discussed with clinicians, pathologists, radiologists, individual patients 
and representatives of patient organizations. Those items judged to be of clear relevance for 
chILD were included in the data dictionary of the register (Table S1) and requested at baseline 
and during visits. A family of measures assessing generic and chILD-specific health-related 
quality of life (HrQoL), and developmentally adapted versions for infants and toddlers, pre-
school children, school children and adolescents is now available on the chILD platform in 
different languages. Proxy ratings of HrQoL can be obtained from the parents, and self-
reports can be provided from children and adolescents 7 years and older. We implemented the 
generic HRQoL scales of the PedsQL
TM
 [15], which has good psychometric properties and is 
available in different European languages. Additionally we developed chILD specific QoL 
scales for each age group. The combination of generic and chILD specific dimensions and 
items allows both comparisons with reference data of other clinical groups or healthy patients 
and the description of chILD specific issues. Additionally, parental quality of life is evaluated 
with the EQ-5D
TM
. Thus, HrQoL serves not only as indicator of the individual patient’s health 
status and assists in determining the need for medical and psychosocial interventions, but also 
changes in QoL outcomes will be an important part of observational and interventional 
studies. 
 For health-economic evaluation a questionnaire was selected based on the validated 
FIMA- Questionnaire for Health-Related Resource Use in an Elderly Population [16]. 
Following direct medical costs (inpatient and outpatient treatment, medical aids and devices, 
informal and formal care) and indirect costs (work absenteeism of the parents and the patient 
due to ILD, if appropriate) will be calculated based on reported utilization volumes by 
applying specific actual unit costs for the distinct services. Additionally travelling costs, 
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operationalized via distance between the healthcare institution and the patient’s place of 
residence will also be included. All questions refer to the previous 3 months. Cost analysis 
enables characterization of high utilizers on patient and subgroup level. 
Reviewer teams 
 Experts identified were those senior specialists of the five participating centers who 
were specialized in pediatric lung pathology, pediatric radiology and pediatric pneumology. 
Each of the countries was initially involved with a team. Due to availability and volunteering 
experts participated in the peer review process. After set up and training of the teams 
members can be mixed internationally as needed. 
Collection and analysis of materials 
 Collection of initial samples of biomaterials in the central biobank was successful in 
most cases including from Germany, UK and Turkey. As shipping of BAL and frozen tissue 
had to be on dry ice, this was a hindrance, and only a minority of subjects had lavages in their 
collections in the biobank. Follow-up samples were supplied by a few centers only.  
Data output and sharing 
 An overview of the individual patient´s data and biomaterials entered can be obtained 
by the treating center. Coordinators can produce lists of patients with a specific diagnosis or 
based on other features. There is a separate export tool available, allowing output of any data 
into several different formats for further statistical analysis. For clinical research investigators 
are invited to produce short proposals and submit them to the project steering committee for 
discussion of feasibility and scientific merit. Common rules regarding the participation in the 
research and the publication of results obtained in projects are described in detail on the 
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website of the kids-lung register foundation (www.kids-lung-register.eu). For statistical 
analysis output into SAS, SPSS or other formats is used. 
Investigator initiated randomized controlled trials selection, set up and administration 
A major goal of the chILD-platform was the identification of areas of greatest need for 
randomized trials by a consensus process and to initiate first pilot trials. In a Delphi-process 
involving all groups included in the initial chILD-EU project, as well as many other experts in 
pediatric pneumology from European countries and the US, the surfactant dysfunction 
disorders were identified as the most important group of molecularly and histologically 
defined entities to be addressed. Mutations in genes encoding for surfactant protein C, the 
lipid transporter ABCA3, thyroid transcription factor 1 and others, cause chILD with high 
morbidity and early mortality [17]. Unfortunately there is no treatment available. 
Hydroxychloroquine (HCQ) has been used empirically for these disorders [18] and is a 
potential lead compound for this group of diseases. The highest priority for further study in 
clinical trials was thus assigned to HCQ as being the greatest patient needs, there being wide 
off-label usage, and from the results of a worldwide Delphi process and recommendations 
from members of the Committee for Orphan Medicinal Products (COMP). A randomized 
phase 2b double blind clinical study, which allows either the initiation or the withdrawal of 
HCQ was commenced and patients were included after peer-review. The primary objective is 
to investigate if HCQ improves oxygenation compared to placebo. Secondary objectives of 
the project are to generate important knowledge on other parameters, as indicated above. 
Further details on the study were deposited at clinicaltrials.gov (NCT02615938).  
 The other area of unmet need identified is the treatment of extrinsic allergic alveolitis 
(EAA) or hypersensitivity pneumonitis [19]. Treatment primarily is based on removal of the 
patient from the suspected etiologic exposure. However, allergen exposure may remain high 
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despite these efforts. Glucocorticoid treatment is given routinely to accelerate recovery and 
because complete removal from allergen exposure is difficult to achieve. The study is parallel 
group (NCT02631603) with the primary endpoint being change in forced vital capacity (FVC) 
with prednisolone after 6 months, compared to change from placebo.  
The investigator initiated trials on the platform separately underwent ethics review, approval 
by competent authorities and administrative contracts; again, this was no small task across 
Europe. 
 
Discussion 
Local hurdles to include subjects into registers  
 A major obstacle for a local site physician caring for a subject with a rare disease and 
willing to enter a patient into the register is the discrepancy between the wish and the work 
load to accomplish this. An estimated time of 120 min is necessary to collect the clinical data, 
fill them into forms, either electronically or on paper, an additional 30 min to have radiology 
imagines burnt on CD, shipped to central site or upload into the system if trained 
appropriately, an additional 60 to 120 min to organize and ship pathology materials and other 
biomaterials and 30 min to write a brief case description. Thus about 5h have to be spent 
before the discussion and peer review of a case can start. Man-power for this and resources 
necessary for shipping are usually not available in busy hospitals. This immediately explains 
that 190 of 575 patients included into the register had insufficient data precluding the start of 
the peer review. These patients were mainly from centers outside the consortium and lacking 
any support, except the one given by the register, to enter their cases. Beyond automatic 
reminders by the SecuTrial® system briefly before and 4 weeks after a regularly scheduled 
visit, in case of missing data all centers were reminded individually at least twice from within 
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the electronic system and also by direct emailing. A major conclusion from this data is the 
need for local financial site support when cases are included into the register, and importantly 
during long term follow up. 
Administrative hurdles within Europe for investigator-initiated studies in rare pediatric 
respiratory diseases 
Among the largest obstacles faced for the development of novel treatments of rare and 
ultra-rare pediatric respiratory conditions is the lack of a functioning international clinical trial 
network. It is extremely difficult to find significant numbers of subjects and families willing 
to participate in clinical trials, as cohorts to observe the natural history are not available for all 
entities. Close collaboration with patient organizations will help, but many countries do not 
have such organizations. Established cohorts of subjects with rare entities are prerequisites for 
successful winning of research awards; however funding bodies frequently do not appreciate 
the rarity of these diseases. Novel funding strategies, e.g. stretching relatively low budgets 
over 6 to 10 years for many institutions, are necessary to collect sufficient rare cases.  
Additional problems are generated by current regulatory rules, established previously 
for diseases with a higher prevalence. Such rules are unnecessarily burdensome and 
obstructive for investigator initiated studies in rare diseases. Many “low hanging, but 
extremely important fruits” cannot be harvested. These encompass a multitude of off-label 
treatments which are given to the patients anyway in an uncontrolled and heterogeneous 
fashion, as well as diagnostic procedures which were never assessed and are only done 
because they have always been done by clinicians in a certain way. Patients with the same 
disease are treated differently in different centers and outcomes are never compared. However 
due to current legislation it is legally not possible to enroll such subjects into simple 
randomized investigations. Administrative hurdles are so high that they cannot reasonably be 
overcome and studies will never be done.  
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An additional level of complexity is added by the fact that all the different European 
countries need different competent authority applications and different insurance policies. 
Nothing can be done efficiently, using a single approach. All authorities come up with similar, 
but somewhat different suggestions, which do not improve, but merely delay the process. All 
this is extremely costly and cumbersome to organize for non-commercial interest groups, such 
as clinicians caring for patients. Ethics applications are sometimes even more fragmented. For 
example in Germany all local ethics board give their valuable comments for approval.  
Lastly, contracts between administrations, contracts with hospital pharmacies, and 
contracts with local research organizations are needed before a subject can be studied. Site 
staff needs not only to be trained but also to demonstrate conformity with GCP with regularly 
updated re-certification. The recently established ERIC (European Research Infrastructure 
Consortium) and earlier ECRIN (European Research Infrastructure Consortium) networks 
may be of substantial help. The EMA is aware of some of these problems however solutions 
which work have not been achieved [21]. The chILD community is currently ill-served by all 
these national and EU regulations.  
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Supplemental Figures  
 
Fig S1 
 
Organizational and data safety concept of chILD-EU register and biobank. After patient 
consent and completion of the paperwork to register as a center, the local site physician logs 
into the data base and deposits patient identification data (IDAT) on a separate server 
administering the central patient list and generating a patient identification number (PID). A 
project specific subject identification code (SIC) is returned and the local site physician enters 
the medical data, which are stored on a different server and linked to the SIC. An 
identification number for biomaterials is also entered into the data base. This sample ID is 
used for shipping of bio-samples to the biobank for storage. The biobank is completely 
separated from the medical data base.  
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Fig S2 
 
 
Organizational concept of chILD-EU biobank. The biobank administers and stores 
biomaterial independent of medical data in order to avoid identification of subjects via 
their biomaterials. The local site physician links biomaterials to medical data by entering 
the sample identification under the subject identification code (SIC) into the register. 
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Fig S3 
 
 
Distribution of the age at inclusion of the 346 patients with peer-review 
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Form Parameter
Demographics Consent
Demographics Birthdate
Demographics Gender
Demographics Country name
Demographics Age at database inclusion (in years)
Family and Neonatal history Death/sick from interstitial lung disease
Family and Neonatal history Death/sick from other disease (under age 60 year)
Family and Neonatal history Race/Ethnics of MOTHER
Family and Neonatal history Race/Ethnics of FATHER
Family and Neonatal history Consanguinity
Family and Neonatal history Chronic illness or death of relatives
Family and Neonatal history Gestational age
Family and Neonatal history Birth weight
Family and Neonatal history Any respiratory problems
Family and Neonatal history Neonatal oxygen supplementation
Family and Neonatal history Neonatal ventilation
Vital Signs, lung function and pulmonary hypertension Respiratory rate
Vital Signs, lung function and pulmonary hypertension Height
Vital Signs, lung function and pulmonary hypertension Weight
Vital Signs, lung function and pulmonary hypertension Body-Mass-Index (BMI)
Vital Signs, lung function and pulmonary hypertension Heart rate
Vital Signs, lung function and pulmonary hypertension O2 saturation
Vital Signs, lung function and pulmonary hypertension O2-flow
Vital Signs, lung function and pulmonary hypertension O2-saturation with room air challenge
Vital Signs, lung function and pulmonary hypertension Flow air
Vital Signs, lung function and pulmonary hypertension Flow O2
Vital Signs, lung function and pulmonary hypertension FiO2
Vital Signs, lung function and pulmonary hypertension PEEP
Vital Signs, lung function and pulmonary hypertension PIP
Vital Signs, lung function and pulmonary hypertension Respiratory rate
Vital Signs, lung function and pulmonary hypertension FiO2
Vital Signs, lung function and pulmonary hypertension Ti (inspiration time)
Vital Signs, lung function and pulmonary hypertension MPAW (Mean airway pressure)
Vital Signs, lung function and pulmonary hypertension PaO2 (Partial pressure of oxygen in arterial blood) 
Vital Signs, lung function and pulmonary hypertension PcapO2 (Partial pressure of oxygen in capillary blood)
Vital Signs, lung function and pulmonary hypertension FEV1
Vital Signs, lung function and pulmonary hypertension FVC
Vital Signs, lung function and pulmonary hypertension MEF 25/75
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Vital Signs, lung function and pulmonary hypertension DLCO
Vital Signs, lung function and pulmonary hypertension 6 min. walk distance
Vital Signs, lung function and pulmonary hypertension Borg Scale
Vital Signs, lung function and pulmonary hypertension Pulmonary hypertension
Vital Signs, lung function and pulmonary hypertension Fan 5 point severity scale
 Radiology Images and Findings CT/X-Ray
Genetics Gene mutation
Genetics Chromosomal Abnormality or Array Comparative Genomic Hybridization (array CGH) Abnormality
Histology, EMI - images Histology, EMI - images
Laboratory tests LDH
Laboratory tests ANA [Autoantibody screen]
Laboratory tests c-ANCA [Proteinase 3 ANCA, i.e. Wegener]
Laboratory tests p-ANCA [Myeloperoxidase ANCA, i.e. Churg-Strauss Syndrome]
Laboratory tests GMCSF-autoantibodies [Autoimmune alveolar proteinosis]
Laboratory tests Bird IgG antibodies [bird precipitines]
Laboratory tests Fungus IgG antibodies [fungi precipitines]
Laboratory tests Aspergillus lgE
Laboratory tests Immunoglobulines - IgG
Laboratory tests Immunoglobulines - IgM
Laboratory tests Immunoglobulines - IgA
Laboratory tests Immunoglobulines - IgE
Laboratory tests Hb
Laboratory tests Eosinophils
Laboratory tests White cell count (absolute)
Radiology images and findings Imaging
Lung biopsy - report Lung biopsy - report
Lung biopsy - additional Pathology - report Lung biopsy - additional Pathology - report
Bronchoalveolar lavage (BAL) Recovery
Bronchoalveolar lavage (BAL) Viability
Bronchoalveolar lavage (BAL) Total number of cells
Bronchoalveolar lavage (BAL) Macrophages
Bronchoalveolar lavage (BAL) Lymphocytes
Bronchoalveolar lavage (BAL) PMN
Bronchoalveolar lavage (BAL) EOS
Bronchoalveolar lavage (BAL) Plasma cells
Bronchoalveolar lavage (BAL) PAS stain
Bronchoalveolar lavage (BAL) Iron + Mac
Bronchoalveolar lavage (BAL) Fat + Mac
Medical history Date interstitial lung disease (ILD) first suspected
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Medical history Start of chronic lung disease symptoms
Medical history Primary ciliary dyskinesia
Medical history Cystic fibrosis comment
Medical history Clinical course of lung disease 
Medical history Pulmonary exacerbation 
Medical history Cough 
Medical history Dyspnea 
Medical history Tachypnoe 
Medical history Fine crackles 
Medical history Wheezing 
Medical history Gastro-esophageal reflux, clinically relevant 
Medical history Hemoptysis 
Medical history Recurrent asprations 
Medical history Recurrent otitis 
Medical history Recurrent lower airway infections/pneumonia 
Medical history Failure to thrive / Weight loss 
Medical history Autoimmune disease 
Medical history Immunodeficiency / HIV/Aids 
Medical history Blood disease 
Medical history Heart disease 
Medical history Intestine disease 
Medical history Kidney disease 
Medical history Liver disease 
Medical history Lymphatic system disease 
Medical history Musculoskeletal system disease 
Medical history Nervous system disease 
Medical history Skin disease 
Medical history Thyroid gland disease 
Medical history Other disease 
Medical history Exposure to bird/fungal antigens 
Prophylaxis Recommended basic immunisations 
Prophylaxis Influenza, annual shot 
Prophylaxis RSV, monthly shots during season 
Prophylaxis Immunoglobulins i.v./s.c. 
Treatment Anticoagulants 
Treatment Azathioprine 
Treatment Calcium channel blocker 
Treatment Cyclophosphamide 
Treatment ECMO / other support 
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Treatment Endothelin receptor antagonist 
Treatment Hydroxychloroquine 
Treatment Lung transplant listing 
Treatment Macrolide, long term 
Treatment Mycophenolate 
Treatment NO (inhaled) 
Treatment Non invasive ventilation 
Treatment Oxygen supplementation 
Treatment Phosphodiesterase inhibitor 
Treatment Pirfenidon 
Treatment Prostaglandines 
Treatment Steroids, systemic 
Treatment Surgery of the airways, lung, thorax 
Treatment Surgery of the intestine (PEG, Fundoplicatio)
Treatment Ventilation (invasive, except neonatal ventilation) 
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Nr Pulmonary diagnosis Non pulmonary diagnosis Check correct Category and Subcategory
1 x B1 - DPLD-related to systemic disease processes - Storage diseases
B1 - DPLD-related to systemic disease processes - Immune-mediated/collagen vascular disorders
B2 - DPLD-in the presumed immune intact host, related to exposures (infectious/non-infectious) - Drug Reactions
A4 - DPLD–related to alveolar surfactant region - Nonspecific interstitial pneumonia (NSIP)
A2 - DPLD-Growth abnormalities deficient alveolarisation - Related to chromosomal disorders
2 x A4 - DPLD–related to alveolar surfactant region - ABCA3 mutations 2
A2 - DPLD-Growth abnormalities deficient alveolarisation - Related to chromosomal disorders
A4 - DPLD–related to alveolar surfactant region - ABCA3 mutations 1
A4 - DPLD–related to alveolar surfactant region - Chronic pneumonitis of infancy (CPI)
A4 - DPLD–related to alveolar surfactant region - Usual interstitial pneumonitis
3 x A2 - DPLD-Growth abnormalities deficient alveolarisation - Related to preterm birth (BPD-cLDI)
A2 - DPLD-Growth abnormalities deficient alveolarisation - Pulmonary hypoplasia
A2 - DPLD-Growth abnormalities deficient alveolarisation - Related to preterm birth (Wilson Mikity, new BPD)
A2 - DPLD-Growth abnormalities deficient alveolarisation - Related to chromosomal disorders
A1 - DPLD-Diffuse developmental disorders - Congenital alveolar dysplasia
4 A3 - DPLD-Infant conditions of undefined etiology - Chronic tachypnoe of infancy (CTI)
A3 - DPLD-Infant conditions of undefined etiology - Chronic tachypnoe of infancy (CTI), aberrant
x A3 - DPLD-Infant conditions of undefined etiology - Neuroendocrine cell hyperplasia of infancy (NEHI)
A3 - DPLD-Infant conditions of undefined etiology - Chronic tachypnoe of infancy (CTI), usual
Ax - DPLD-unclear RDS in the mature neonate - Familial
5 A4 - DPLD–related to alveolar surfactant region - PAP, juvenile
x A4 - DPLD–related to alveolar surfactant region - PAP histopattern +
A4 - DPLD–related to alveolar surfactant region - PAP, secondary to associated disease
A4 - DPLD–related to alveolar surfactant region - NSIP, PAP pattern
A3 - DPLD-Infant conditions of undefined etiology - Pulmonary interstitial glycogenosis (PIG) primary
6 A2 - DPLD-Growth abnormalities deficient alveolarisation - Related to preterm birth (BPD-cLDI)
x A2 - DPLD-Growth abnormalities deficient alveolarisation - Related to preterm birth (Wilson Mikity, new BPD)
B1 - DPLD-related to systemic disease processes - Alagille Syndrome (arteriohepatic dysplasia)
B1 - DPLD-related to systemic disease processes - Diffuse alveolar hemorrhage due to vasculitic disorders
A4 - DPLD–related to alveolar surfactant region - Nkx21 gene defect
7 D - Airway disorders - Bronchitis
B2 - DPLD-in the presumed immune intact host, related to exposures (infectious/non-infectious)  - Mac-Leod-Swyer-James-Syndrom
B1 - DPLD-related to systemic disease processes - Storage diseases
x B2 - DPLD-in the presumed immune intact host, related to exposures (infectious/non-infectious) - Infectious/post-infectious processes
B3 - DPLD-in the immunocompromised host or transplanted - Infections–Miscellaneous
8 A4 - DPLD–related to alveolar surfactant region - NSIP, DIP pattern
A4 - DPLD–related to alveolar surfactant region  - NSIP, fibrotic
A4 - DPLD–related to alveolar surfactant region - Nonspecific interstitial pneumonia (NSIP)
A4 - DPLD–related to alveolar surfactant region - NSIP +/- DIP +/- PAP pattern
x A4 - DPLD–related to alveolar surfactant region - NSIP, cellular
9 Ax - DPLD-unclear RDS in the mature neonate - Familial
B1 - DPLD-related to systemic disease processes - Stevens-Johnson Syndrome-idiopathic+BO
x By - DPLD-unclear NON-neonate - Unclear DPLD/ILD
Bx - DPLD-unclear RDS in the NON-neonate - Familial
B2 - DPLD-in the presumed immune intact host, related to exposures (infectious/non-infectious) - Infectious/post-infectious processes
10 B2 - DPLD-in the presumed immune intact host, related to exposures (infectious/non-infectious) - Aspiration syndromes+BO
B2 - DPLD-in the presumed immune intact host, related to exposures (infectious/non-infectious) - Bronchiolitis without Transplantation
D - Airway disorders - Aspirations, recurrent
Interstital lung disease with mixed type of
NSIP-Pattern, DIP-Pattern with focal 
intraalveolar Cholesterin granulomas 
(Cholesterinpneumonitis) and focal 
 discrete PAP-Pattern
No Mutation in the ABCA3- and SPC-
gene detected
Adrenoleucodystrophy
DPLD from 2 ABCA3 mutations
DPLD probabely related to surfactant 
 metabolism disorder
Bronchopulmonary dysplasia
Prematurity
Persistent tachypnea of infancy; 
 aberrant; 
Neuroendocrine cell hyperplasia of 
infancy
Alveolar proteinosis of unknown origin 
DD postinfectious
DD GMCSF-Ab mediated
DD related to GMCSF-beta mutation
On lung biopsy alveolar proteinosis, yet 
of unknown origin
Battered child
 Wilson Mikity Snydrome
Chronic lung disease of prematurity 
 (29+2)
 Status after neonatal infection
Centroacinar emphysema
 DPLD related to infections
- Bronchiolitis (maybe obliterans) with 
 prebronchiectasis
 Asthma
NSIP, cellular pattern
 Atelectasis right UL
Hyperplasia of neuroendocrine cells 
 (sign of immaturity)
 IRDS, familial.
Overinflated lungs with prominent 
bronchovascular structures.
Dystrophy, 11 ribs
Chronic suprative lung disease with 
bronchiolitis, atelectasis and ground glas 
attenuation; biochemical Surfactant 
Protein C - (SP-C)-Deficiency;  DD  
secundary to infection, or recurrent 
pneumonia.  
Sepsis with pneumococcus 05/2013
Failure to thrive
1. Suppurative lung disease with 
secondary involvement of the lungs from 
infections, DD aspirations, DD ILD (acc. 
t di l i t i ) 2 C t l
1. Psychomotoric retardation, 2. 
Muscular hypotonia, 3. Diabetes 
insipidus centralis, 4. Growth 
h d fi i 5 Ch i
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x D - Airway disorders - Chronic Bronchitis
D - Airway disorders - Bronchitis
11 B2 - DPLD-in the presumed immune intact host, related to exposures (infectious/non-infectious) - Infectious/post-infectious processes
x B2 - DPLD-in the presumed immune intact host, related to exposures (infectious/non-infectious) - Bronchiolitis obliterans
B1 - DPLD-related to systemic disease processes - Stevens-Johnson Syndrome-infection related+BO
F - Lung infections- Mycoplasma Pneumoniae 
B3 - DPLD-in the immunocompromised host or transplanted - Infections–Miscellaneous
12 B3 - DPLD-in the immunocompromised host or transplanted - Interferonopathy
B1 - DPLD-related to systemic disease processes - Immune-mediated/collagen vascular disorders
B2 - DPLD-in the presumed immune intact host, related to exposures (infectious/non-infectious) - Infectious/post-infectious processes
B3 - DPLD-in the immunocompromised host or transplanted - Diffuse lung damage of unknown etiology
x B3 - DPLD-in the immunocompromised host or transplanted - LIP
13 B3 - DPLD-in the immunocompromised host or transplanted - Follicular bronchitis/bronchiolitis
B3 - DPLD-in the immunocompromised host or transplanted - Diffuse lung damage of unknown etiology
x B3 - DPLD-in the immunocompromised host or transplanted - Related to Tx or rejection+BO
B3 - DPLD-in the immunocompromised host or transplanted - BO
B3 - DPLD-in the immunocompromised host or transplanted - Related to transplantation and rejection
14 B1 - DPLD-related to systemic disease processes - Microscopic Polyangiitis
B3 - DPLD-in the immunocompromised host or transplanted - Related to therapeutic intervention
B1 - DPLD-related to systemic disease processes - Undifferentiated connective tissue disease
B2 - DPLD-in the presumed immune intact host, related to exposures (infectious/non-infectious) - Acute Fibrinous and Organizing Pneumonia
x B1 - DPLD-related to systemic disease processes - Immune-mediated/collagen vascular disorders
15 A3 - DPLD-Infant conditions of undefined etiology - Neuroendocrine cell hyperplasia of infancy (NEHI)
x A3 - DPLD-Infant conditions of undefined etiology - Chronic tachypnoe of infancy (CTI)
By - DPLD-unclear NON-neonate - Unclear DPLD/ILD
A4 - DPLD–related to alveolar surfactant region - Chronic pneumonitis of infancy (CPI)
A3 - DPLD-Infant conditions of undefined etiology - Chronic tachypnoe of infancy (CTI), aberrant
16 A2 - DPLD-Growth abnormalities deficient alveolarisation - Pulmonary hypoplasia
A2 - DPLD-Growth abnormalities deficient alveolarisation - Related to preterm birth (BPD-cLDI)
x A2 - DPLD-Growth abnormalities deficient alveolarisation - Related to chromosomal disorders
A2 - DPLD-Growth abnormalities deficient alveolarisation - Related to preterm birth (Wilson Mikity, new BPD)
Ay - DPLD-unclear RDS in the almost (30-36 wks) mature neonate - Familial
17 x C1 - Localized, congenital gross structural abnormalities of the lungs - Infantile Lobar Emphysema/Polyalveolar Lobe
A1 - DPLD-Diffuse developmental disorders - Congenital alveolar dysplasia
A1 - DPLD-Diffuse developmental disorders - Alveolar Dysgenesis/Primary Pulmonary Hypoplasia
A2 - DPLD-Growth abnormalities deficient alveolarisation - Pulmonary hypoplasia
D - Airway disorders - Emphysema
18
B1 - DPLD-related to systemic disease processes - Diffuse alveolar hemorrhage due to vasculitic disorders
B1 - DPLD-related to systemic disease processes - Idiopathic pulmonary capillaritis
B1 - DPLD-related to systemic disease processes - Immune-mediated/collagen vascular disorders
B4 - DPLD-related to lung vessels structural processes - Pulmonary hemorrhage due to coagulopathy
x B4 - DPLD-related to lung vessels structural processes - Pulmonary hemorrhage
19 A4 - DPLD–related to alveolar surfactant region - Nonspecific interstitial pneumonia (NSIP)
B2 - DPLD-in the presumed immune intact host, related to exposures (infectious/non-infectious) - Infectious/post-infectious processes
x B2 - DPLD-in the presumed immune intact host, related to exposures (infectious/non-infectious) - Exogen allergic alveolitis/hypersensitivity pneumonitis
B2 - DPLD-in the presumed immune intact host, related to exposures (infectious/non-infectious) - Drug Reactions+BO
B2 - DPLD-in the presumed immune intact host, related to exposures (infectious/non-infectious) - Bronchiolitis without Transplantation
20 A4 - DPLD–related to alveolar surfactant region - Nonspecific interstitial pneumonia (NSIP)
to radiologist peer review), 2. Central 
 and obstruive apnoe-CPAP
hormone deficiency, 5.Chronic 
sinusitis maxillaris+surgery of 
adenoids 2x, 6. Excision 
papilloma uvula, 7. Enlarged 
lymph nodes mediastinum
Bronchiolitis obliterns, post Mycoplasma 
 (2009) DD Stevens-Johnson-Syndrom, 
DD Erythema exsudative major
Recurrent Stomatitis, sometimes 
with conjunctivitis and 
exanthema
Likely genetically caused disorder, 
 e.g.IPEX related; histo lymphocytic 
alveolits, interstitial lung disease LIP 
 pattern)
 Partial respiratory insufficiency
Recurrent pneumonia
NYHA III-IV, chronic 
Inflammation disease of the 
intestine with chronic diarhoe, 
exocrine pancreatic insufficienc, 
dystrophi, chronic recurrent 
arthralgia, severe GERD
Bronchiolitis obliterans following 
haematopoietic stem cell transplantatio, 
respiratory failure, chronic Pseudomonas
aeruginosa lung infection (since 
 02/2011), recurrent infective 
exacerbations, recurrent 
pneumothoraces (06/2011, 03/2012, 
 05/2012, 01/2013, 02/2013), unilateral 
 pleurodesis (left), wedge resection 
apical left
Haematopoietic stem cell 
 transplantation (11/2009)
Busulfan conditioning prior to 
 transplantation
Acute myeloid leukemia (AML), 
 relapsed
 Chronic GvHD
Failure to Thrive
chILD in a patient with rheumatologic 
 disease (MCTD)
 No radiological signs for LIP.
 Pulmonary arterial hypertension
Respiratory Failure
Mixed connective tissue disease 
with oligoarthritis, uveitis, 
pancreatitis, hepatitis
Persistent tachypnea of infancy
Premature (36+2, SGA), recurrent lower 
respiratory tract infection, pulmonary 
 hypertension
Consistent with TTF1 defect
Trisomy 22 (cat eyes 
 syndrome)
hypothroidy, hypotonia, agenesis 
of corpus callosum 
 Congenital lobar emphysema
Residuals from infection (CMV, other 
 bugs)
 
Suspected pulmonary hemosiderosis  Thrombosis of sinus venosus
Death after blood Transfusion in 
other hospital
Hypersensitive pneumonitis, but it is 
atypical 
NSIP - cellular, follicular bronchiolitis Atrial septal defect, 
Pneumocystis infection
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x B3 - DPLD-in the immunocompromised host or transplanted - NSIP
B3 - DPLD-in the immunocompromised host or transplanted - NSIP and BO
B3 - DPLD-in the immunocompromised host or transplanted - Diffuse lung damage of unknown etiology
Bx - DPLD-unclear RDS in the NON-neonate - Familial
21 A3 - DPLD-Infant conditions of undefined etiology - Neuroendocrine cell hyperplasia of infancy (NEHI)
A4 - DPLD–related to alveolar surfactant region - Usual interstitial pneumonitis
x A3 - DPLD-Infant conditions of undefined etiology - Chronic tachypnoe of infancy (CTI), aberrant
B2 - DPLD-in the presumed immune intact host, related to exposures (infectious/non-infectious) - Infectious/post-infectious processes
A4 - DPLD–related to alveolar surfactant region - Chronic pneumonitis of infancy (CPI)
22 B3 - DPLD-in the immunocompromised host or transplanted - Lymphoid hyperplasia
x B3 - DPLD-in the immunocompromised host or transplanted - Related to therapeutic intervention
B3 - DPLD-in the immunocompromised host or transplanted - Infections–Miscellaneous
B3 - DPLD-in the immunocompromised host or transplanted - Related to transplantation and rejection
B2 - DPLD-in the presumed immune intact host, related to exposures (infectious/non-infectious) - Drug Reactions
23
x Ax - DPLD-unclear RDS in the mature neonate- Familial
A4 - DPLD–related to alveolar surfactant region - Chronic pneumonitis of infancy (CPI)
Ax - DPLD-unclear RDS in the mature neonate - Pulmonary hypertension
By - DPLD-unclear NON-neonate - Unclear DPLD/ILD
A2 - DPLD-Growth abnormalities deficient alveolarisation - Pulmonary hypoplasia
24
x B2 - DPLD-in the presumed immune intact host, related to exposures (infectious/non-infectious) - Bronchiolitis obliterans
B2 - DPLD-in the presumed immune intact host, related to exposures (infectious/non-infectious) - Respiratory Bronchiolitis-Interstitial Lung Disease (RB-ILD)
B1 - DPLD-related to systemic disease processes - Stevens-Johnson Syndrome-idiopathic+BO
B1 - DPLD-related to systemic disease processes - Stevens-Johnson Syndrome-infection related+BO
D - Airway disorders - Chronic Bronchitis
25 B4 - DPLD-related to lung vessels structural processes - Pulmonary capillary hemangiomatosis
B4 - DPLD-related to lung vessels structural processes - Pulmonary hemorrhage due to vascular disorder
B4 - DPLD-related to lung vessels structural processes - Pulmonary hemorrhage due to infection
B1 - DPLD-related to systemic disease processes - Immune-mediated/collagen vascular disorders
x B1 - DPLD-related to systemic disease processes - Idiopathic pulmonary hemosiderosis
Pneumocystis infection, 
hypoglycemia at birth, 
hypogammaglobulinemia
Chronic tachypnea of infancy (CTI)
Pulmonary hemosiderosis of unknown 
origin, diffuse lung disease with 
emphysematous lesions as well as signs 
for growth anomalies with multiple 
interfissural blebs
Pectus deformity
Severe diffuse lung disease, 
radiologicaly consistent with 
pleuroparenchymal fibroelastosis after 
high dose chemotherapy and bone 
marrow transplant
Neuroblastoma, tumor lysis 
syndrome, recurrent severe 
infections, poor nutrition
Undefined interstitial lung disease with 
neonatal onset (In an older child you 
would be looking at diffuse pulmonary 
haemorrhage, extremely rare in 
neonates)                         
As per radiology discussion there 
appears to be non-specific ground glass, 
with some elements of aspiration. 
Similar case in a previous sibling, 
died from as mature infant from 
neonatal respiratory distress
The HRCT and the biopsy are both 
compatible with distal airway disease 
(chronic bronchiolitis) which we have not 
infrequently encountered 
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Tab S3 Diagnoses altered by peer review 
Nr Initial pulmonary diagnosis Peer review pulmonary diagnosis Cate-
gory 
Specification 
(primarily due to)* 
Therapy change 
observed** 
1 Alveolar proteinosis, DD alveolar capillary dysplasia 
with misalignement of the pulmonary veins 
Diffuse developmental disorder. ACD with or without 
(both status observed in same tissue) misalignment, 
likely with, as patient died soon. Of interest is the 
radiological diagnosis of PAP; may be due to surfactant 
applied previously 
A1 specified diagnosis 
by adding relevant 
info 
(pathology) 
Y 
Palliative 
treatment 
2 Severe Respiratory failure, ECMO, Suggested chILD 
developmental disorder or growth anomaly, 
Chylothorax, Pulmonal arterial hypertension with 
suprasystemic pressure and persistent fetal 
circulation 
Alveolar dysplasia, chylothorax and lymphangiectasia of 
the lungs with severe respiratory failure, ECMO. 
Pulmonary arterial hypertension (suprasystemic), 
persistent fetal circulation. Pulmonary interstitial 
glycogenosis (PIG) 
A1 specified diagnosis 
by adding relevant 
info 
(pathology) 
N  
Palliative 
treatment 
3 Interstitial lung disease with obstructive and 
(pseudo)restrictive ventilatory dysfunction with 
emphysema and fibrosis on chest CT. Severe RDS in 
an almost term-born child (36+5 weeks gestations) 
with mechanical ventilation over 10 days. 
Continuous oxygen dependency in the first months 
of life. Persistent hypoxemia with frequent 
exacerbations and oxygen requirement in viral 
infections 2009-2012 and 2015. Intermittent 
hypoxemia with home oxygen supply 
Pulmonary hypertension in association with small 
patella Syndrome, possibly due to TBX4 mutations. 
Histology: in parts alveolar-capillary dysplasia without 
misalignment 
A1 specified diagnosis 
was made 
(genetics) 
Y 
Stop hydroxy-
chloroquine 
4 Interstitial lung disease Wilson Mikity syndrome, chronic lung disease of 
prematurity (29+2), status after neonatal infection, 
centro-acinar emphysema 
A2 specified diagnosis 
was made 
(clinical, imaging) 
Y 
Stop systemic 
steroids 
5 Alveolar capillary dysplasia without misalignement 
of the pulmonary veins, chronic oxygen 
dependency, ventilator dependent respiratory 
failure since June 2015, pulmonary hypertension 
Trisomy 21 with abnormal alveolarization and 
associated PIG 
A2 specified diagnosis 
by adding relevant 
info 
(pathology) 
Y 
Start systemic 
steroids 
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6 Unclear lung disease Recurrent chylothoraces, respiratory decompensation. 
Pulmonary hypertension. No evidence for interstitial 
lung disease. Recurrent atelectasis and lung infections. 
Possibly on the basis of alveolo-vascular abnormalities 
with Noonan-Syndrome 
A2 wrong diagnosis 
(clinical, genetics) 
Y 
Stop systemic 
steroids 
7 suspected postinfectious BO (Rhinovirus infection) Neuroendocrine cell hyperplasia A3 wrong diagnosis 
(pathology) 
Y 
Stop systemic 
steroids 
8 Parenchymal lung disease. Suspected infection 
with Pneumocystis jirovecii (mild positive in PCR). 
Partial respiratory insufficiency 
Chronic tachypnoea of infancy, aberrant type. 
Neuroendocrine cell hyperplasia 
A3 wrong diagnosis 
(pathology) 
Y 
Stop systemic 
steroids, stop 
long term 
macrolide 
9 Airway inflammation with recurrent infections, 
suspicion of chILD 
Chronic tachypnea of infancy, Neuroendocrine cell 
hyperplasia 
A3 wrong diagnosis 
(pathology) 
Y 
Start long term 
macrolide, stop 
inhaled 
salbutamol 
10 Interstitial lung disease Chronic pneumonitis of infancy; related recurrent 
pulmonary infections, related to immunodeficiency 
A3 specified diagnosis 
was made 
(pathology) 
N 
 
11 Interstitial lung disease Chronic tachypnoe of infancy; neuroendocrine cell 
hyperplasia by histology; CT Shows in addition some 
consolidation and linear markings. Aberrant 
neuroendocrine cell hyperplasia 
A3 specified diagnosis 
was made 
(pathology) 
Y 
Stop long term 
macrolide 
12 Interstitial lung disease Persistent tachypnea of infancy, neuroendocrine cell 
hyperplasia on biopsy; aberrant form 
A3 specified diagnosis 
was made 
(pathology) 
Y 
No medical 
treatments given 
13 interstitial lung disease Neuroendocrine cell hyperplasia A3 specified diagnosis 
was made 
(pathology) 
Y 
Stop systemic 
steroids 
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14 Interstitial Pneumonitis Chronic tachypnea of infancy. Almost mature (35 wks), 
no postnatal respiratory distress. Since wk 2 chronic 
tachypnea. Since 8 mon O2 supplementation at 
night/or for sleeping 
A3 wrong diagnosis 
(clinical, imaging) 
Y 
Stop 
azathioprine, 
systemic steroids 
15 Suspected ILD (steroid sensitive).Post-pneumonia. 
Acute respiratory decompensation. Lung edema 
Diffuse parenchymal lung disease with the histological 
pattern of Neuroendocrine cell hyperplasia (Steroid 
sensitive). Chronic respiratory failure with continuous 
Oxygen/high flow dependency and hypercapnia. 
Recurrent severe lower respiratory infections with 
Deterioration of the underlying disease 
A3 specified diagnosis 
by adding relevant 
info 
(pathology) 
Y 
Stop systemic 
steroids 
16 Surfactant metabolism or production disorder Mild alveolar hypoplasia. PIG pattern. Post infectious 
lung disease with focal obliterative bronchiolitis in 
histology. Post inflammatory minimal residual 
intraalveolar fibrin, few interstitial inflammatory cells, 
interstitial edema, focal hyperplasia of type II 
pneumocytes. Bilateral pneumothoraces 
A3 wrong diagnosis 
(pathology) 
Y 
Stop macrolides 
and 
hydroxychloroqui
ne 
17 Interstitial pneumonitis of unknown etiology. 
Persistent nocturnal oxygen requirement (1 l/min). 
Asthma 
Chronic tachypnea of infancy A3 specified diagnosis 
by adding relevant 
info 
(clinical, imaging) 
Y 
Stop systemic 
steroids 
18 Pulmonary interstitial glycogenosis (PIG) Persistent tachypnea of infancy, aberrant, lung biopsy 
not conclusive for PIG 
A3 specified diagnosis 
by adding relevant 
info 
(pathology) 
N 
19 Suspected lung fibrosis, respiratory insufficiency, 
tachypnoea 
Surfactant dysfunction syndrome due to ABCA3 
mutations 
A4 specified diagnosis 
was made 
(genetics) 
Y 
Start hydroxy-
chloroquine, 
azathioprine 
20 Severe neonatal respiratory distress, respiratory 
failure, ventilator-dependent, presently HFO-
Ventilation, minimum peep required 11 torr 
chILD related to inherited Surfactant metabolism 
disorder (ABCA3 mutations) 
A4 specified diagnosis 
was made 
(genetics) 
Y 
Start systemic 
steroids, hydroxy-
chloroquine  
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21 Suspected interstitial Lung disease, recurrent 
bronchitis, prolonged pneumonia 2004 with 
persistent cyanosis 
NSIP, fibrosing A4 specified diagnosis 
was made 
(pathology) 
Y 
Stop systemic 
steroids 
22 Suspected ILD, tachypnea DPLD (NSIP cellular) related to SP-C deficiency A4 specified diagnosis 
was made 
(pathology, 
genetics) 
Y 
Stop systemic 
steroids 
23 Suspected CVID, recurrent pulmonary infections, 
chronic interstitial lung disease, steroid-
dependence, intermittent O2 need, secondary 
pulmonary hypertension, chronic atrophic 
bronchitis 
TTF1 Deficiency with (a) pulmonary symptoms 
(Ureaplasma postnatal, prolongend ventilation, 
recurrent pneumonia/Bronchitis) (b) mild 
developmental retardation. (c) pulmonary hypertension 
(d) IgG deficiency 
A4 wrong diagnosis 
(genetics) 
Y 
Stop long term 
macrolides 
24 Unexplained IRDS Interstitial lung disease from compound heterozygous 
ABCA3 mutations 
A4 specified diagnosis 
was made 
(genetics) 
Y 
Palliative 
treatment 
25 Interstitial lung disease - unknown cause NSIP, follicular bronchiolitis, pneumocystis infection A4 specified diagnosis 
was made 
(pathology) 
y  
Stop systemic 
steroids 
26 Respiratory distress Syndrome. Pneumonia, 
unknown lung disease 
Diffuse lung disease related to surfactant dysfunction 
disorder 
A4 specified diagnosis 
was made 
(genetics) 
Y 
Stop systemic 
steroids 
27 Interstitial lung disease Desquamative interstitial pneumonia in a mature 
neonate with respiratory distress syndrome 
A4 specified diagnosis 
by adding relevant 
info 
(pathology) 
Y 
Start hydroxy-
chloroquine, 
azathioprine, 
systemic steroids 
28 Pulmonary fibrosis of unknown origin, respiratory 
failure type 1, hypoxemia since first year of life, 
pulmonary arterial hypertension, secondary 
Pseudomonas aerugionsa infection 
Filamin-A Mutation with pulmonary arterial 
hypertension, secondary emphysema, fibrosis, 
respiratory failure 
B1 specified diagnosis 
was made 
(genetics) 
Y 
Stop hydroxy-
chloroquine, 
azathioprine 
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29 Severe restrictive lung disease, pulmonary cysts 
and bullae. exercise induced dyspnea since 
October 2014 
Langerhans cell histiocytosis B1 specified diagnosis 
was made 
(pathology) 
Y 
Start cladribin 
30 Suspected Williams-Campbell-Syndrome. Status 
post resection right upper- and middle lobe 
Diffuse lung disease probably related to Filamin A -
mutation 
B1 wrong diagnosis 
(imaging, 
pathology) 
N 
31 Interstitial lung disease BO, likely post-infectious B2 specified diagnosis 
was made 
(clinical, imaging) 
Y 
Start long term 
macrolide 
32 Interstitial lung disease Hypersensitivity pneumonitis due to feathers B2 specified diagnosis 
was made 
(clinical, imaging) 
Y 
Stop systemic 
steroids 
33 Interstitial lung disease Post-infectious obliterative bronchiolitis B2 specified diagnosis 
was made 
(clinical, imaging) 
Y 
Inhaled steroids 
34 Neuroendocrine hyperplasia of infancy, previous 
34 weeks infant, parainfluenza bronchiolitis 2014 
Post-infectious obliterative bronchiolitis B2 specified diagnosis 
by adding relevant 
info 
(clinical, imaging) 
Y 
Inhaled ß-
adrenergics 
35 Interstitial lung disease of unknown origin, maybe 
related to SP-C-dysfunction (father with severe ILD 
and same radiological pattern), may be 
hypersensitivity pneumonitis (positive precipitins 
against bird feather and positive exposition) 
Chronic hypersensitivity pneumonitis B2 specified diagnosis 
was made 
(clinical, imaging, 
pathology) 
Y 
Improve allergen 
removal, reduce 
systemic steroids 
36 Interstitial lung disease Post infectious bronchiolitis (may be obliterans?) with 
mosaic perfusion peripheral air trapping and pseudo-
restriction 
B2 specified diagnosis 
by adding relevant 
info 
(clinical, imaging) 
Y 
Start systemic 
steroids 
37 Combined restrictive and obstructive lung disease Progressive virus triggered and P ae entertained 
bronchiolitis obliterans syndrome (BOS) after SCT with 
pulmonary hemorrhages 
B3 specified diagnosis 
was made 
(clinical, imaging) 
Y 
Start long term 
macrolide 
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38 Interstitial lung disease. RDS IV° with intubation 
and surfactant therapy twice after birth. Invasive 
ventilation (HFO, SIMV) for six days, noninvasive 
ventilation (CPAP, HighFlow) intermittently, 
persistent oxygen requirement and hypercapnia 
Immune deficiency with A-gamma-globulinemia. 
Previous Pneumocystis infection. RDS IV° of the almost 
mature. Interstitial lung disease with pattern of 
DIP+PMN and CPI+CIP. Obstructive apnea, retrognathia 
B3 specified diagnosis 
by adding relevant 
info 
(clinical, pathology) 
Y 
Start 
Cotrimoxazol, 
Amoxicillin, 
systemic steroids 
39 Recurrent infection of the respiratory tract. 
Interstitial lung disease 
Lymphocytic Interstitial pneumonia. Protracted 
bacterial infection. Bronchiectasis. Recurrent otitis. 
Recurrent sinusitis 
B3 specified diagnosis 
by adding relevant 
info 
(pathology) 
Y 
Continue 
mycophenolate 
and start 
antibiotics 
40 Interstitial lung disease Lymphocytic interstitial pneumonia. Recurrent chest 
infections. Tracheo-bronchomegaly (Mounier-Kuhn-
Syndrome) 
B3 specified diagnosis 
was made 
(pathology) 
Y 
Start systemic 
steroids 
41 Interstitial lung disease (not defined) Idiopathic pulmonary hypertension. No interstitial lung 
disease 
B4 wrong diagnosis 
(clinical, imaging) 
Y 
Start long term 
macrolide (infec-
tious reason) 
42 Suspected CTI/Neuroendocrine cell hyperplasia. 
Recurrent obstructive Bronchitis. Respiratory 
partial insufficiency. Status post protracted 
bacterial bronchitis 
Protracted bacterial bronchitis with chronic wet cough 
responsive to antibiotic treatment. Multi-trigger 
wheeze, bronchial hyper-reactivity with response to 
ICS/LTRA's. Intermittent, not chronic tachypnea. CT: 
minimal, but not suggestive signs for neuroendocrine 
cell hyperplasia 
D wrong diagnosis 
(clinical, imaging) 
N 
43 Interstitial Inflammation. Interstitial Fibrosis. 
William-Campbell syndrome. Allergic asthma 
(house dust mite allergy) 
Cystic fibrosis; non-classical form. Interstitial 
inflammation and fibrosis. Allergic asthma (house dust 
mite allergy) 
D wrong diagnosis 
(clinical, imaging) 
Y 
Airway clearance, 
antibiotics 
44 Interstitial inflammation. Interstitial Fibrosis. 
William-Campbell syndrome. Sibling of previous 
case. 
Postinfectious Bronchiolitis. Bronchiectasis based on 
cystic fibrosis; non-classical form. 
D wrong diagnosis 
(clinical, imaging) 
Y 
Airway clearance, 
antibiotics 
*The means by which altered peer review pulmonary diagnosis was primarily based on: clinical, imaging, pathology, genetics data 
**Change in therapy observed following peer review. Usually no specific treatment changes were recommended by peer review 
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